Aliment Pharmacol Ther 2001: 15: 2043–2066.

Index

^{13}C-galactose breath test, 1975
^{13}C-urea breath analyser, 389
^{13}C-urea breath test, 73, 505, 1001, 1205, 1499
1-week regimen, 81
5-aminosalicylic acid, 53, 1131
5-ASA, 1549
5-HT$_3$ receptor agonists, 1717, 1745
5-HT$_4$ receptor, 1655
5-hydroxytryptamine 4 partial agonist, 937
6-mercaptopurine monitoring, 1699

α1-microglobulin, 363
absorption, 45
accuracy, 703
achalasia, 1389
acid clearance, 1385
acid inhibition, 379, 1163, 1929
acid rebound, 105
acid secretion, 813, 821, 1753, 1795
acid suppression, 221, 519, 1989
acid suppressive therapy, 639
acid, 1929
acromegaly, 181
Actis, G.C., Bresso, F., Astegiano, M., Demarchi, B., Sapone, N., Boscaglia, C. & Rizzetto, M. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis, 1307
active duodenal ulcer, 1037
active immunisation, 1989
active ulcerative colitis, 251
acute cholangitis, 1633
acute diarrhoea, 773
acute gastrointestinal haemorrhage, 1109
Adachi, K. *see* Ishihara, S.
Adachi, K., Ishihara, S., Hashimoto, T., Hirakawa, K., Ishimura, N., Niigaki, M., Kaji, T., Kawamura, A., Sato, H., Fujishiro, H., Hattori, S., Watanabe, M. & Kinoshita, Y. Efficacy of ecabet sodium for *Helicobacter pylori* eradication triple therapy in comparison with a lansoprazole-based regimen, 1187
adenomas, 631
Adlis, S.A. *see* Shaw, M.J.
adsorbent, 773
adverse drug reaction reporting systems, 475
adverse drug reactions, 171, 475
adverse effects, 171
aetiology, 337, 1875
Affì, A. *see* Hernandez, L.V.
age, 171, 937, 1473
Aghdassi, E. *see* Carrier, J.
aging, 1031
Ahmad, T., Satsangi, J., McGovern, D., Bunce, M. & Jewell, D.P. Review article: the genetics of inflammatory bowel disease, 731
AIDS, 1619
Aithal, G.P. & Mansfield, J.C. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment, 1101
Ajjan, R. *see* Trudgill, N.J.
Ajjan, R.A. *see* Hussain, F.N.
Akram, S. *see* Goodgame, R.W.
Alaimo, G. *see* Di Marco, V.
alanine aminotransferase, 241
Albillos, A. *see* Calleja, J.L.
Alexander, J.S. *see* Oshima, T.
Alizadeh, B.Z. *see* Fakheri, H.
Allard, J.P. *see* Carrier, J.
Allocca, M. *see* Battezzati, P.M.
Almasio, P.L. *see* Di Marco, V.
alosetron, 525
altered bowel function, 1655
Alvisi, V. *see* The British-Italian Gallstone Study Group
Amati, L. *see* Cozzolongo, R.
aminosalicylic acid, 363
amoxicillin, 613, 1031, 1787
anaemia, 429
anal fissures, 887
Andersson, T., Röhss, K., Bredberg, E. & Hassan-Alin, M. Pharmacokinetics and pharamcodynamics of esomeprazole, the S-isomer of omeprazole, 1563
Andriulli, A. *see* Perri, F.
Andriulli, A. *see* Testoni, P.A.
Angeletti, S. *see* Corleto, V.D.
angiogenesis, 2017
Annese, V. *see* Perri, F.
Annibale, B. *see* Capurso, G.
Annibale, B. *see* Corleto, V.D.
antacid, 1365
Anti, M. *see* Armuzzi, A.
antibacterial agents, 1543
antibiotic prophylaxis, 1883
antibiotic resistance, 487, 1787
antibiotic susceptibility, 493, 1199
antibiotic therapy, 163
antibiotics, 1017, 1023, 1827
antibody, 699
anti-diarrhoeal, 773
anti-gastrin antibody, 1989
anti-inflammatory action, 257

© 2001 Blackwell Science Ltd

antimicrobial resistance, 1473
antimicrobial, 773
antioxidant vitamins, 1997
antioxidant, 2035
antiretroviral agents, 1627
anti-secretory drug therapy, 269
antisecretory effect, 1563
antisense oligodeoxynucleotides, 1673
anti-ulcer medications, 1769
apoptosis, 989, 1087, 1271, 1301, 1467
Appel-Dingemanse, S. *see* Degen, L.
Appel-Dingemanse, S., Horowitz, A., Campestrini, J., Osborne, S. & McLeod, J. The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects—male and female, elderly and young, 937
Arguedas, M.R., Heudebert, G.R. & Wilcox, C.M. Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis, 631
Armuzzi, A., Cremonini, F., Bartolozzi, F., Canducci, F., Candelli, M., Ojetti, V., Cammarota, G., Anti, M., De Lorenzo, A., Pola, P., Gasbarrini, G. & Gasbarrini, A. The effect of oral administration of *Lactobacillus GG* on antibiotic-associated gastrointestinal side-effects during *Helicobacter pylori* eradication therapy, 163
Arnott, I.D.R., McDonald, D., Williams, A. & Ghosh, S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience, 1639
arterial bleeding, 1109
Asaka, M. *see* Hokari, K.
Asaka, M. *see* Ikeda, S.
aspirin, 539, 677, 865, 1055
Assendelft, W.J.J. *see* Hurenkamp, G.J.B.
Astegiano, M. *see* Actis, G.C.
α-tocopherol, 1667
ATP synthesis, 1837
atrophic gastritis, 805, 1163
atrophy, 1819
Aubé, A.-C. *see* Plattner, V.
Avasthy, N. *see* Galmiche, J.P.
Avidan, B., Sonnenberg, A., Giblovich, H. & Sontag, S.J. Reflux symptoms are associated with psychiatric disease, 1915
Avidan, B., Sonnenberg, A., Schnell, T.G. & Sontag, S.J. Walking and chewing reduce postprandial acid reflux, 151
Avni, Y. *see* Shirin, H.
Ayoub, A. *see* Ortiz, J.J.
azathioprine, 1307, 1699
azithromycin, 1787
Azuma, T., Ito, Y., Suto, H., Ohtani, M., Dojo, M., Muramatsu, A., Kuriyama, M. & Kato, T. The effect of *Helicobacter pylori* eradication therapy on dyspepsia symptoms in industrial workers in Japan, 805

bacampicillin, 1787
bacterial antigens, 1647
Baerg, R.D. *see* Vakil, N.B.
Bagnolo, F. *see* Testoni, P.A.
Baird, A. *see* McCormack, G.
balsalazide, 1549
Balzano, A. *see* Manes, G.
Bandekar, R.R. *see* Scheiman, J.M.
Banerjee, P. *see* Xue, S.
Bang, C. *see* Talley, N.J.
Barbara, G. *see* De Giorgio, R.
Bardhan, K.D. & Van Rensburg, C. (on behalf of the investigators). Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omepraxole in patients with grade I reflux oesophagitis, 1585
Bardhan, K.D. *see* Müller-Lissner, S.A.
Bardhan, K.D., Morton, D., Perry, M.J., Sanders, D.S., Morris, P., Rowland, A., Thompson, M., Mitchell, T.R. & Roberts, P.M. Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of *Helicobacter pylori*, 1199
Barr, H., Dix, A.J., Kendall, C. & Stone, N. Review article: the potential role for photodynamic therapy in the management of upper gastrointestinal disease, 311
Barrett's oesophagus, 221, 269, 311, 519, 899, 1087
Barrowman, N. *see* Redstone, H.A.
Bartelsman, J.W.F.M. *see* Vreeburg, E.M.
Barthélemy, P. *see* Laurent, J.
Bartolozzi, F. *see* Armuzzi, A.
basic fibroblast growth factor, 1673
Basson, M.D., Panzini, L. & Palmer, R.H. Effect of nabumetone and aspirin on colonic mucosal bleeding time, 539
Battezzati, P.M., Zuin, M., Crosignani, A., Allocca, M., Invernizzi, P., Selmi, C., Villa, E. & Podda, M. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients, 1427
Bax, 989
Bayes formula, 1403
Bazzoli, F., Palli, D., Zagari, R.M., Festi, D., Pozzato, P., Nicolini, G., Masala, G., Fossi, S., Ricciardiello, L., Panuccio, D. & Roda, E. The Loiano-Monghidoro population-based study of *Helicobacter pylori* infection: prevalence by ^{13}C-urea breath test and associated factors. , 1001
Bcl-2, 989
Beales, I.L.P. Letter to the Editors, 727
Beane, A. *see* Hull, M.
Beaugerie, L., Berenbaum, F., Berrebi, D., Gendre, J.P., Prier, A., Kaplan, G. & Chatelet, F.P. Chronic use of non-steroidal anti-inflammatory drugs does not alter colonic mucosa of patients without diarrhoea, 1301
Bebb, J.R. & Logan, R.P.H. Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?, 1843
Becker, J.C. *see* Pohle, T.
Beebe, T.J. *see* Shaw, M.J.
Beglinger, C. *see* Degen, L.
Bell, N., Karol, M.D., Sachs, G., Greski-Rose, P., Jennings, D.E. & Hunt, R.H. Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers, 105
Bellini, M. *see* Costa, F.
Beltrami, M. *see* Vecchi, M.
Benhamou, Y. *see* Poynard, T.
Benson, M.J. *see* Zar, S.

© 2001 Blackwell Science Ltd

benzodiazepines, 1915
Berenbaum, F. *see* Beaugerie, L.
Beretta, L. *see* Vecchi, M.
Berg, D.E. *see* Wong, B.C.Y.
Bernasconi, G. *see* Testoni, P.A.
Berni Canani, R. *see* Carroccio, A.
Berrebi, D. *see* Beaugerie, L.
Bertold, R. *see* Degen, L.
Bharucha, A.E. *see* Coulie, B.
Biagi, G. *see* De Giorgio, R.
Bidaut-Mazel, C. *see* Bruley Des Varannes, S.
Bielanski, W. *see* Konturek, P.C.
bile acids and salts (treatment), 123
bile reflux, 1375
bile, 1435
bioavailability, 973
biofeedback, 1147
biologically-derived secretin, 669
Birbeck, N. *see* Selvasekar, C.R.
Birkenfeld, S. *see* Shirin, H.
bismuth subsalicylate, 513
Bjarnason, I. *see* Jacob, M.
Bjarnason, I. *see* Tibble, J.
Blackshaw, P.E. *see* Perkins, A.C.
bleeding time, 539
bleeding ulcer, 1109
bleeding, 821
Bleiberg, H. *see* Buecher, B.
bloating, 1655
Blomqvist, P., Feltelius, N., Löftberg, R. & Ekbom, A. A 10-year survey of inflammatory bowel diseases—drug therapy, costs and adverse reactions, 475
blood transfusion, 1109
Bochenek, W.J. *see* Osato, M.S.
Bolognese, J.A. *see* Hawkey, C.J.
bone turnover, 783
Bordi, C. *see* Capurso, G.
Borro, P. *see* Giannini, E.
Bortolotti, M., Mari, C., Lopilato, C., La Rovere, L. & Miglioli, M. Sildenafil inhibits gastroduodenal motility, 157
Boscaglia, C. *see* Actis, G.C.
Botta, F. *see* Giannini, E.
botulinum toxin injection, 1389
bowel habit, 1139
Bowen, J. *see* Hull, M.
Bozzola, L. *see* Pilotto, A.
Brading, A.F. *see* Cook, T.A.
Brasch, H. *see* Leodolter, A.
Brattsand, R. *see* Miller-Larsson, A.
Bravo, J.C. *see* Fischbach, L.A.
Bravo, L.E. *see* Fischbach, L.A.
Brazowski, E. *see* Dotan, I.
breath tests, 1763
Bredberg, E. *see* Andersson, T.
Brenna, E. *see* Humphries, T.J.
Bresso, F. *see* Actis, G.C.
Bruck, R. *see* Shirin, H.
Bruley Des Varannes, S., Fléjou, J.F., Colin, R., Zaïm, M., Meunier, A. & Bidaut-Mazel, C. There are some benefits for eradicating *Helicobacter pylori* in patients with non-ulcer dyspepsia, 1177
Brullet, E. *see* Calvet, X.
Brummer, R.-J.M. *see* Schoon, E.J.
Brundler, R. *see* Netzer, P.
Brune, K. *see* Dormann, H.
Bruzzese, E. *see* Carroccio, A.
Brzozowski, T. *see* Pohle, T.
Buchanan, M. *see* Metz, D.C.
budesonide CIR (Entocort), 1331
budesonide, 45, 2027
Buecher, B. & Bleiberg, H. Review article: non-systemic chemotherapy in the treatment of colorectal cancer—portal vein, hepatic arterial and intraperitoneal approaches, 1527
Bühling, A., Radun, D., Müller, W.A. & Malfertheiner, P. Influence of anti-*Helicobacter* triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora, 1445
Bunce, M. *see* Ahmad, T.
Burton, D. *see* Coulie, B.
buspirone, 1613
Bytzer, P. *see* Jones, R.
Bytzer, P., Talley, N.J., Jones, M.P. & Horowitz, M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus, 137

C57BL/6 mice, 875
Caekaert, A. *see* Laurent, J.
cag island, 1271
Calam, J. *see* Fitzgerald, A.J.
Caldwell, C. *see* Tibble, J.
Calleja, J.L., Albillos, A., Rossi, I., Moreno, R., Domper, F., Martínez, J.L. & Escartín, P. Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response, 241
caloric density, 233
Calvet, X. *see* Gisbert, J.P.
Calvet, X., Garcia, N., Gené, E., Campo, R., Brullet, E. & Sanfeliu, I. Modified seven-day, quadruple therapy as a first line *Helicobacter pylori* treatment, 1061
Calvet, X., Gené, E., López, T. & Gisbert, J.P. What is the optimal length of proton pump inhibitor-based triple therapies for *H. pylori*? A cost-effectiveness analysis, 1067
Camilleri, M. Review article: tegaserod, 277
Camilleri, M. *see* Coulie, B.
Cammarota, G. *see* Armuzzi, A.
Campestrini, J. *see* Appel-Dingemanse, S.
Campieri, M. *see* Vecchi, M.
Campo, R. *see* Calvet, X.
Campo, S.M.A. *see* Zullo, A.
cancer, 899
Candelli, M. *see* Armuzzi, A.
Canducci, F. *see* Armuzzi, A.
Canducci, F., Ojetti, V., Pola, P., Gasbarrini, G. & Gasbarrini, A. Letter to the Editors, 143

© 2001 Blackwell Science Ltd

Capurso, G., Annibale, B., Osborn, J., D'Ambra, G., Martino, G., Lahner, E. & Delle Fave, G. Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and *Helicobacter pylori* infection. , 821
Capurso, G., Lahner, E., Marcheggiano, A., Caruana, P., Carnuccio, A., Bordi, C., Delle Fave, G. & Annibale, B. Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with *Helicobacter pylori* infection, 1753
Caradonna, L. *see* Cozzolongo, R.
carbohydrate, 1139
Carnoy's fixation, 1485
Carnuccio, A. *see* Capurso, G.
Carr, E. *see* Dinan, T.G.
Carrier, J., Aghdassi, E., Platt, I., Cullen, J. & Allard, J.P. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. , 1997
Carroccio, A., Guarino, A., Zuin, G., Verghi, F., Berni Canani, R., Fontana, M., Bruzzese, E., Montalto, G. & Notarbartolo, A. Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients, 1619
Carter, M.J. *see* Parsons, H.K.
Carty, E., Rampton, D.S., Schneider, H., Rutgeerts, P. & Wright, J.P. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease, 1323
Caruana, P. *see* Capurso, G.
Casabon, A.L. *see* Fischbach, L.A.
case control study, 483
Castell, D.O. *see* Katz, P.O.
Castell, D.O. *see* Srinivasan, R.
Castell, D.O. *see* Xue, S.
celecoxib, 2009
cell cycle, 1087
cell division, 1077, 1681
cell proliferation, 1077, 1681
Ceuppens, J. *see* Cornillie, F.
Ceuppens, J.L. *see* Colpaert, S.
Ch'ng, C.L. *see* Hawkes, N.D.
Chamberlin, W., Graham, D.Y., Hulten, K., El-Zimaity, H.M.T., Schwartz, M.R., Naser, S., Shafran, I. & El-Zaatari, F.A.K. Review article: *Mycobacterium avium* subsp. *paratuberculosis* as one cause of Crohn's disease, 337
Chan, C.K. *see* Wong, B.C.Y.
Chan, C.K. *see* Xia, H.H.-X.
Chan, F.K.L. *see* Leung, W.K.
Chan, F.K.L. *see* To, K.F.
Chan, F.K.L. *see* Tsang, S.W.C.
Chan, F.K.L. *see* Wu, J.C.Y.
Chan, F.K.L. *see* Yu, J.
Chan, F.K.L., Sung, J.J.Y., Ching, J.Y.L., Wu, J.C.Y., Lee, Y.T., Leung, W.K., Hui, Y., Chan, L.Y., Lai, A.C.W. & Chung, S.C.S. Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs, 19
Chan, F.K.L., To, K.F., Ng, Y.P., Lee, T.L., Cheng, A.S.L., Leung, W.K. & Sung, J.J.Y. Expression and cellular localization of COX-1 and -2 in *Helicobacter pylori* gastritis, 187
Chan, H.-H. *see* Hsu, P.-I.
Chan, H.L.Y. *see* Tsang, S.W.C.
Chan, H.L.-Y., Tang, J.-L., Tam, W. & Sung, J.J.-Y. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis, 1907
Chan, L.Y. *see* Chan, F.K.L.
Chan, W.Y. *see* Yu, J.
Chatelet, F.P. *see* Beaugerie, L.
Chau, T.N. *see* Tsang, S.W.C.
Chegne, N.L. *see* Ortiz, J.J.
chemoprevention, 631
chemotherapy, 1527
Chen, C.-L. *see* Orr, W.C.
Chen, M. *see* Paul, K.
Chen, W. *see* Hsu, P.-I.
Cheng, A.S.L. *see* Chan, F.K.L.
Cheng, A.S.L. *see* To, K.F.
Cheng, J.-S. *see* Hsu, P.-I.
Cheng, N.-N. *see* Chinese National Cooperative Study Group For Helicobacter Pylori
chenodeoxycholic acid, 123
Cherbut, C. *see* Plattner, V.
Chernew, M.E. *see* Scheiman, J.M.
Cheuk, C.Y. *see* Li, Y.
Cheung, K.L. *see* Wong, W.M.
Chiarbonello, B. *see* Giannini, E.
Chiba, K. *see* Shirai, N.
Chien, E.-J. *see* Hsu, P.-I.
childhood gastritis, 203
children, 595
China, 81
Chinese National Cooperative Study Group For Helicobacter Pylori: Xiao, S.-D., Liu, W.-Z., Hu, P.-J., Ouyang, Q., Wang, J.-L., Zhou, L.-Y. & Cheng, N.-N. A multicentre study on eradication of *Helicobacter pylori* using four 1-week triple therapies in China, 81
Ching, J.Y.L. *see* Chan, F.K.L.
Chiu, Y.L. *see* Täubel, J.J.
Cho, C.H. *see* Li, Y.
Cho, C.H. *see* Wong, B.C.Y.
cholecystectomy, 1233
cholecystokinin, 181, 1357
cholinesterase inhibitors, 1717
Chong, R.Y., Hanauer, S.B. & Cohen, R.D. Efficacy of parenteral methotrexate in refractory Crohn's disease, 35
Chow, T.P. *see* Leung, W.K.
Christie, S. *see* Cummings, J.H.
chronic gastritis, 1177
chronic hepatitis B infection, 1737
chronic hepatitis C, 129
chronic hepatitis, 857
chronic inflammatory colitis, 1301
Chu, K.M. *see* Wong, B.C.Y.
Chun Yu Wong, B., Ping Wang, W., Hau Leung So, W., Shin, V.Y., Man Wong, W., Man Yee Fung, F., Shiu Lam Liu, E.,

© 2001 Blackwell Science Ltd

Mo Hiu, W., Kum Lam, S., Hin Cho, C. Epidermal growth factor and its receptor in chronic active gastritis and gastroduodenal ulcer before and after *Helicobacter pylori* eradication, 1459
Chung, S.C.S. *see* Chan, F.K.L.
Chung, S.C.S. *see* Leung, W.K.
Chung, S.C.S. *see* Yu, J.
cimetidine, 917, 1291
Ciociola, A.A. *see* Robinson, M.
cirrhosis, 689, 857
cisapride, 1385
citric acid, 1763
clarithromycin, 403, 411, 487, 613, 707, 851, 1031, 1445, 1493, 1861
clinical trial, 513, 831, 959, 1907
coagulation, 539
codeine, 625
Coelho, G. *see* Gálvez, J.
coeliac disease, 1417
Cohen, R.D. *see* Chong, R.Y.
Cola, B. *see* De Giorgio, R.
colchicine, 1427
Cole, T.J. *see* Cummings, J.H.
Colin, R. *see* Bruley Des Varannes, S.
Colin-Jones, D.G. *see* Sheen, C.L.
colitis, 731, 1219, 1997
collagenous colitis, 1301
Collazos, T. *see* Fischbach, L.A.
Collins, J.K. *see* O'Mahony, L.
colon cancer, 1673
colon cleansing, 605
colon, 539, 653, 1301
colorectal cancer, 323, 451, 1527
colorectal carcinoma, 631
Colpaert, S., Liu, Z., De Greef, B., Rutgeerts, P., Ceuppens, J.L. & Geboes, K. Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indomethacin-induced bowel inflammation model, 1827
combination treatment, 1427
complementary and alternative medicine, 1239
compliance, 653
computer monitoring system, 171
concanavalin-A, 1077
Concha, A. *see* Gálvez, J.
congenital abnormalities, 483
Connor, P. *see* Mulcahy, H.E.
constipation, 277, 625, 749, 1655
construct validity, 981
Cook, T.A., Brading, A.F. & Mortensen, N.J.McC. Review article: the pharmacology of the internal anal sphincter and new treatments of ano-rectal disorders, 887
Corder, F.A. *see* Sharma, V.K.
Corinaldesi, R. *see* De Giorgio, R.
Corleto, V.D., Annibale, B., Gibril, F., Angeletti, S., Serrano, J., Venzon, D.J., Della Fave, G. & Jensen, R.T. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger–Ellison syndrome?, 1555
Cornillie, F., Shealy, D., D'Haens, G., Geboes, K., Van Assche, G., Ceuppens, J., Wagner, C., Schaible, T., Plevy, S.E., Targan, S.R. & Rutgeerts, P. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease, 463
Correa, P. *see* Fischbach, L.A.
corticosteroids, 563, 1515
Costa, F., Mumolo, M.G., Bellini, M., Romano, M.R., Manghetti, M., Paci, A., Maltinti, G. & Marchi, S. Post-treatment diagnostic accuracy of a new enzyme immunoassay to detect *Helicobacter pylori* in stools, 395
cost-effectiveness analysis, 1067
cost-effectiveness, 63, 631, 1777
cost-minimization, 1009
Coulie, B., Camilleri, M., Bharucha, A.E., Sandborn, W.J. & Burton, D. Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects, 653
COX-2, 2009
coxibs, 1593
Cozzolongo, R., Cuppone, R., Giannuzzi, V., Amati, L., Caradonna, L., Tamborrino, V., Jirillo, E. & Manghisi, O.G. Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to inteferon, 129
Craxi, A. *see* Di Marco, V.
Cremonini, F. *see* Armuzzi, A.
Crespo, M.E. *see* Gálvez, J.
Criegee-Rieck, M. *see* Dormann, H.
Crohn's disease, 35, 45, 337, 363, 371, 463, 475, 563, 731, 783, 1101, 1131, 1313, 1323, 1331, 1515, 1639, 1647, 1699, 1861, 1867
Crosignani, A. *see* Battezzati, P.M.
Crotta, S. *see* Testoni, P.A.
Cruchet, S. *see* Gotteland, M.
Cruz, T. *see* Gálvez, J.
crypt branching, 1077, 1681
crypt fission, 1077, 1681
Cullen, J. *see* Carrier, J.
culture, 1023
Cummings, J.H., Christie, S. & Cole, T.J. A study of fructo oligosaccharides in the prevention of travellers' diarrhoea, 1139
Cuppone, R. *see* Cozzolongo, R.
Curry, J.I., Lander, T.D. & Stringer, M.D. Review article: erythromycin as a prokinetic agent in infants and children, 595
cyclin, 1505
cyclooxygenase 2 inhibitors, 631
cyclooxygenase, 25, 187
cyclooxygenase-2, 875
cyclosporin, 665, 1307
CYP2C19 genetic polymorphism, 1479
CYP2C19 genotypes, 793, 1937
cystatin C, 1131
cytochrome P-450, 1975
cytokines, 463, 1699, 1709
Czeizel, A.E. *see* Nørgård, B.

© 2001 Blackwell Science Ltd

D'Amato, M. *see* Trudgill, N.J.
D'Ambra, G. *see* Capurso, G.
D'Amico, D. *see* Vakil, N.B.
D'Haens, G. *see* Cornillie, F.
Dalros, L. *see* Fennerty, M.B.
Dansereau, R.J. *see* Perkins, A.C.
De Boer, W.A. *see* Janssen, M.J.R.
De Bruïne, A. *see* Sanduleanu, S.
De Franchis, R. *see* Vecchi, M.
De Giorgio, R., Barbara, G., Stanghellini, V., Tonini, M., Vasina, V., Cola, B., Corinaldesi, R., Biagi, G. & De Ponti, F. Review article: the pharmacological treatment of acute colonic pseudo-obstruction, 1717
De Greef, B. *see* Colpaert, S.
De Lorenzo, A. *see* Armuzzi, A.
De Matthaeis, M. *see* Zullo, A.
De Ponti, F. *see* De Giorgio, R.
De Wit, N.J. *see* Weijnen, C.F.
decision analysis, 63, 631
Degen, L., Matzinger, D., Merz, M., Appel-Dingemanse, S., Osborne, S., Lüchinger, S., Bertold, R., Maecke, H. & Beglinger, C. Tegaserod, a 5-HT_4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects, 1745
Dekker, W. *see* Geboes, K.
Delchier, J.C. *see* Tankovic, J.
Della Fave, G. *see* Corleto, V.D.
Delle Fave, G. *see* Capurso, G.
Delle, M. *see* Talley, N.J.
Demarchi, B. *see* Actis, G.C.
Deventer, S.J.H.V. *see* Vreeburg, E.M.
dextran sulphate sodium, 1997
Di Marco, V., Vaccaro, A., Ferraro, D., Alaimo, G., Rodolico, V., Parisi, P., Peralta, S., Di Stefano, R., Almasio, P.L. & Craxi, A. High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C, 953
Di Mario, F. *see* Pilotto, A.
Di Maurizio, P. *see* Vecchi, M.
Di Stefano, R. *see* Di Marco, V.
diabetes mellitus, 137
diagnosis, 699, 1763
diarrhoea, 277, 1139, 1409, 1889
diet, 773
dietary elimination and challenge, 439
dietary recommendations, 233
Dillon, J.F. *see* Todd, J.A.
Dinan, T.G., Mahmud, N., Rathore, O., Thakore, J., Scott, L.V., Carr, E., Naesdal, J., O'Morain, C.A. & Keeling, P.W.N. A double-blind placebo controlled study of buspirone-stimulated prolactin release in nonulcer dyspepsia—are central serotoninergic responses enhanced?, 1613
Dindzans, V.J. *see* Hernandez, L.V.
Dipalma, J.A. *see* Toledo, T.K.
direct costs, 945
disodium cromoglycate, 439
dissolution, 123
Dix, A.J. *see* Barr, H.
dog, 1233
Dojo, M. *see* Azuma, T.
Domek, M. *see* Netzer, P.
Domper, F. *see* Calleja, J.L.
Domschke, W. *see* Pohle, T.
Dormann, H., Krebs, S., Muth-Selbach, U., Criegee-Rieck, M., Radespiel-Tröger, M., Levy, M., Hahn, E.G., Brune, K. & Schneider, T. Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk?, 171
dosing frequency, 53
Dotan, I., Hershkoviz, R., Karmeli, F., Brazowski, E., Peled, Y., Rachmilewitz, D. & Halpern, Z. Heparin and low-molecular-weight heparin (enoxaparin) significantly ameliorate experimental colitis in rats, 1687
Doulgeroglou, V. *see* Kamberoglou, D.
Dove-Edwin, I. & Thomas, H.J.W. Review article: the prevention of colorectal cancer, 323
Dowling, R.H. *see* Pereira, S.P.
Drewe, J. *see* Meier, R.
drug cost, 475
drug surveillance, 171
drug therapy, 475
dual therapy, 1199
Ducrottè, P. *see* Galmiche, J.P.
Duggan, J.M. Review article: transfusion in gasrointestinal haemorrhage—if, when and how much?, 1109
Dukes, G. *see* Talley, N.J.
duodenal motility, 1929
duodenal mucosa, 1417
duodenal ulcer, 821, 843, 1493, 1593, 1875, 1957
duodenogastric reflux, 1233
duodenum, 157
dyspepsia, 207
dysplasia, 269

early cancer, 311
early detection, 323
Ebert, M.P.A. *see* Yu, J.
ecabet sodium, 1187
ECL cells, 87
Edsbäcker, S. *see* Lundin, P.
education, 1263
Edwards, S.J., Lind, T. & Lundell, L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis, 1729
effectiveness, 1453
efficacy, 1819, 1907
Ehrenpreis, E.D. *see* Hong, J.J.
Ekbom, A. *see* Blomqvist, P.
elderly, 171, 1031
electrical pacemaker, 1115
electrophysiology, 1115
ELISA, 423, 1205
El-Zaatari, F.A.K. *see* Chamberlin, W.
El-Zimaity, H.M.T. *see* Chamberlin, W.
El-Zimaity, H.M.T. *see* Graham, D.Y.
emergency ERCP, 1633

© 2001 Blackwell Science Ltd

endoscopic therapy, 575
endoscopy of GI tract, 945
endoscopy, 1, 539
enteric nervous system, 1717
enteric-release, 625
epidermal growth factor receptor, 1459
epidermal growth factor, 1077, 1459
episodic heartburn, 1571
epithelium, 1077, 1681
eradication failure, 1193
eradication therapy, 805, 1187, 1787
eradication, 195, 203, 417, 1017, 1023, 1543
erosive oesophagitis, 927
erythromycin, 595
erythropoietin, 429
Escartín, P. *see* Calleja, J.L.
esomeprazole, 347, 927, 1563
ethambutol, 1861
Evans, B.K. *see* Hawkes, N.D.
evidence-based medicine, 765
exercise, 151
experimental colitis, 1687
extracorporeal photochemotherapy, 1313

Fackler, W.K., Vaezi, M.F. & Richter, J.E. Ambulatory gastric pH monitoring: proper probe placement and normal values, 1155
faecal chymotrypsin, 1619
faecal elastase-1, 1619
faecal incontinence, 887, 1147
Faigel, D. *see* Fennerty, M.B.
failure, 1017
Fairclough, P.D. *see* Mulcahy, H.E.
Fakheri, H., Malekzadeh, R., Merat, S., Khatibian, M., Fazel, A., Alizadeh, B.Z. & Massarrat, S. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of *Helicobacter pylori* in a population with a high metronidazole resistance rate, 411
famotidine, 1291, 1579
Fang, X.-C. *see* Lu, H.
Farthing, M.J.G. *see* Kelly, P.
Farthing, M.J.G. *see* Mulcahy, H.E.
Fasoli, A. *see* Giannini, E.
fatty liver, 1667
Faure, C., Michaud, L., Khan Shaghaghi, E., Popon, M., Laurence, M., Mougenot, J.F., Hankard, R., Navarro, J. & Jacqz-Aigrain, E. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis, 1397
Favennec, L. *see* Ortiz, J.J.
Fazel, A. *see* Fakheri, H.
Fazel, A. *see* Mikaeli, J.
Febbraro, I. *see* Zullo, A.
Feely, J. *see* Williams, D.
Feeney, M. *see* O'Mahony, L.
Fein, S. *see* Metz, D.C.
Fellermann, K. *see* Herrlinger, K.R.
Feltelius, N. *see* Blomqvist, P.
Fendrick, A.M. *see* Scheiman, J.M.
Fennerty, M.B., Margaret, N., Dalros, L., Faigel, D., Lieberman, D. & Shaw, M. Outcomes of *H. pylori* treatment in community practice and impact of therapeutic effectiveness information on physician behaviour, 1453
Ferraro, D. *see* Di Marco, V.
Festa, V. *see* Perri, F.
Festi, D. *see* Bazzoli, F.
fibrinolysis, 639
Filinto, J. *see* Robinson, M.
Fischbach, L.A., Correa, P., Ramirez, H., Realpe, J.L, Collazos, T., Ruiz, B., Bravo, L.E., Bravo, J.C., Casabon, A.L. & Schmidt, B.A. Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer, 831
fish oil (Eicosapen), 851
Fitzgerald, A.J. *see* Sasaki, M.
Fitzgerald, A.J., Jordinson, M., Rhodes, J.M., Singh, R., Calam, J. & Goodlad, R.A. Comparison of the effects of concanavalin-A and epidermal growth factor on epithelial cell proliferation in the rat intestine, 1077
Fitzgerald, R.C., Lascar, R. & Triadafilopoulos, G. Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression, 269
Fitzgibbon, J. *see* O'Mahony, L.
Fléjou, J.F. *see* Bruley Des Varannes, S.
Fléjou, J.F. *see* Laurent, J.
Fontana, M. *see* Carroccio, A.
food antigens, 1647
food hypersensitivity, 439
food interaction, 45
Forga, L. *see* Labayen, I.
Fornaciari, G. *see* Vecchi, M.
Fossi, S. *see* Bazzoli, F.
Fournet, J. *see* Galmiche, J.P.
Fracchia, M. *see* The British-Italian Gallstone Study Group
Francavilla, A. *see* Ierardi, E.
Francavilla, R. *see* Ierardi, E.
Franceschi, M. *see* Pilotto, A.
Fraser, J.S., Muller, A.F., Smith, D.J., Newman, D.J. & Lamb, E.J. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy, 1131
free radical, 715
Frier, M. *see* Perkins, A.C.
Fujishiro, H. *see* Adachi, K.
Fujishiro, H. *see* Ishihara, S.
Fukuda, R. *see* Ishihara, S.
fulminant hepatic failure, 1737
Fumagalli, A. *see* Giannini, E.
Fumagalli, I. *see* Müller-Lissner, S.A.
functional dyspepsia, 145, 195, 525, 1291, 1603, 1929
Fung, F.M.Y. *see* Wong, B.C.Y.
Fung, F.M.Y. *see* Wong, B.C.Y.
Fung, F.M.Y. *see* Wong, W.M.
furazolidone, 411, 1983
Furuie, H. *see* Horai, Y.
Furuta, T. *see* Shirai, N.
Furuta, T. *see* Xiao, F.

© 2001 Blackwell Science Ltd

Gabriel, R. *see* Gisbert, J.P.
Gaia, C. *see* Netzer, P.
Galatola, G. *see* The British-Italian Gallstone Study Group
gallbladder motility, 181
gallstone disease, 123
gallstones, 181, 1435
Galmiche, J.P. *see* Plattner, V.
Galmiche, J.P., Zerbib, F., Ducrottè, P., Fournet, J., Rampal, P., Avasthy, N. & Humphries, T.J. Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole, 1343
Gálvez, J., Coelho, G., Crespo, M.E., Cruz, T., Rodríguez-Cabezas, M.E., Concha, A., Gonzalez, M. & Zarzuelo, A. Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat, 2035
Gangl, A. *see* Reinisch, W.
Ganio, E. *see* Vecchi, M.
Gao, Q. *see* Verspaget, H.W.
Garcia, N. *see* Calvet, X.
Gardner, J.D. *see* Robinson, M.
Gargala, G. *see* Ortiz, J.J.
Gasbarrini, A. *see* Armuzzi, A.
Gasbarrini, A. *see* Canducci, F.
Gasbarrini, G. *see* Armuzzi, A.
Gasbarrini, G. *see* Canducci, F.
Gasché, C *see* Reinisch, W.
gastric acid, 1155
gastric cancer, 989, 1505
gastric emptying, 543, 1745, 1763
gastric injury, 677
gastric mucosa, 677, 1819
gastric mucus, 2017
gastric pH, 105, 1807
gastric ulcer healing, 2017
gastric ulcer, 25, 1593, 1957
gastrimmune, 1989
gastrin, 989
gastrin-17, 1989
gastrinoma, 1555
gastritis, 87, 831, 1603, 1753
gastroduodenal ulcer, 1459
gastroenterology and hepatology, 171
gastrointestinal motility, 157, 749
gastrointestinal procedures, 605
gastrointestinal symptom survey, 981
gastrointestinal symptoms, 137
gastrointestinal toxicity, 1
gastrointestinal tract, 1077, 1263, 1681
gastrointestinal, 45
gastro-oesophageal reflux disease, 151, 269, 347, 765, 813, 945, 1385, 1915
gastro-oesophageal reflux, 233, 1357
gastropathy, 63
Geboes, K. *see* Colpaert, S.
Geboes, K. *see* Cornillie, F.
Geboes, K., Dekker, W., Mulder, C.J.J. & Nusteling, K. (on behalf of the dutch study group). Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa, 1819
Geerling, B.G. *see* Schoon, E.J.
Geiser, H.R. *see* Meier, R.
gender, 937
Gendre, J.P. *see* Beaugerie, L.
Gené, E. *see* Calvet, X.
genetics, 731
genotype, 493
GERD, 115, 519, 1343, 1351, 1819
Ghosh, S. *see* Arnott, I.D.R.
GI transit, 1745
Giaffer, M. *see* Green, J.R.B.
Giannini, E., Fasoli, A., Borro, P., Chiarbonello, B., Malfatti, F., Romagnoli, P., Botta, F., Testa, E., Fumagalli, A., Polegato, S., Savarino, V. & Testa, R. Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with *Helicobacter pylori* infection, 1975
Giannuzzi, V. *see* Cozzolongo, R.
giardiasis, 1409
Giardullo, N. *see* Manes, G.
Giblovich, H. *see* Avidan, B.
Gibril, F. *see* Corleto, V.D.
Gilson, I. *see* Hernandez, L.V.
Gionchetti, P. *see* Vecchi, M.
Gisbert, J.P. *see* Calvet, X.
Gisbert, J.P., González, L., Calvet, X., Roqué, M., Gabriel, R. & Pajares, J.M. Proton pump inhibitors versus H_2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer, 917
gliadin challenge, 1417
glicentin enteroglucagon, 1681
glyceryl trinitrate, 1867
glycylcycline, 487
Go, M.Y.Y. *see* Leung, W.K.
Go, M.Y.Y. *see* Yu, J.
González, A. *see* Labayen, I.
González, L. *see* Gisbert, J.P.
Gonzalez, M. *see* Gálvez, J.
Goodgame, R.W., Kimball, K., Akram, S., Ike, E., Ou, C.-N., Sutton, F. & Graham, D. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease, 1861
Goodlad, R.A. *see* Fitzgerald, A.J.
Goodlad, R.A. *see* Sasaki, M.
Gorenšek, M. *see* Tepeš, B.
Gotteland, M., Cruchet, S. & Verbeke, S. Effect of *Lactobacillus* ingestion on the gastrointestinal mucosal barrier alterations induced by indomethacin in humans, 11
Graham, D. *see* Goodgame, R.W.
Graham, D.Y. & Reddy, S. Rapid detection of anti-*Helicobacter pylori* IgG in urine using immunochromatography, 699
Graham, D.Y. *see* Chamberlin, W.
Graham, D.Y. *see* Osato, M.S.
Graham, D.Y. *see* Shiotani, A.
Graham, D.Y., Saeed, M.A., Hoffman, J., El-Zimaity, H.M.T., Kwon, D.H. & Osato, M.S. Nitrofurantoin quadruple therapy

© 2001 Blackwell Science Ltd

for *Helicobacter pylori* infection: effect of metronidazole resistance, 513
Green, J., Richardson, C., Marshall, R., Rhodes, J., McKirdy, H., Thomas, G. & Williams, G. Letter to the Editors, 559
Green, J.R.B., Lobo, A.J., Giaffer, M., Travis, S., Watkins, H.C. & The Freedom Investigator Group. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules, 1331
Green, J.T. *see* Hawkes, N.D.
Greski-Rose, P. *see* Bell, N.
Grisham, M.B. *see* Oshima, T.
growth control, 1077, 1681
growth hormone, 181
Grundmeijer, H.G.L.M. *see* Hurenkamp, G.J.B.
guanosine monophosphate, 157
Guarino, A. *see* Carroccio, A.
Gubina, M. *see* Tepeš, B.
Guglielmi, F.W. *see* Ierardi, E.
Guslandi, M. Letter to the Editors, 559
Guslandi, M. Review article: alternative antibacterial agents for *Helicobacter pylori* eradication, 1543
Gustafsson, B. *see* Miller-Larsson, A.
gut mucosa, 2027
gut neuropathology, 1717
Gut, A. *see* Netzer, P.

H_2-antagonists, 765
H_2-blocker, 1291, 1351
H_2RA therapy, 1777
H_2-receptor antagonist, 1291, 1571, 1579
Haber, M.M. *see* Hirschowitz, B.I.
Hadzidakis, A. *see* Matrella, E.
Hadziyannis, A.S., Papaioannou, C., Spanou, F., Manesis, E.K. & Hadziyannis, S.J. Induction interferon therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit, 551
Hadziyannis, S.J. *see* Hadziyannis, A.S.
Hadziyannis, S.J. *see* Papatheodoridis, G.V.
haematemesis, 1109
Hahn, E.G. *see* Dormann, H.
Hahn, E.G. *see* Konturek, P.C.
Halpern, Z. *see* Dotan, I.
Halter, F. *see* Netzer, P.
Hamashima, C. *see* Ikeda, S.
Hamecteman, W. *see* Sanduleanu, S.
Hamelin, B. *see* Vakil, N.B.
Hamilton, M.I., Sercombe, J. & Pounder, R.E. Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine, 1579
Hanai, H. *see* Shirai, N.
Hanai, H. *see* Xiao, F.
Hanaoki, M. *see* Nogi, K.
Hanauer, S.B. *see* Chong, R.Y.
Hankard, R. *see* Faure, C.
Harper, S.E. *see* Hawkey, C.J.
Haruma, K. *see* Nogi, K.
Hase, S. *see* Mizoguchi, H.
Hasegawa, T., Yoneda, M., Nakamura, K., Makino, I. & Terano, A. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study, 1667
Hashimoto, T. *see* Adachi, K.
Hashimoto, T. *see* Ishihara, S.
Hassan, C. *see* Zullo, A.
Hassan-Alin, M. *see* Andersson, T.
Hata, J. *see* Nogi, K.
Hathaway, S. *see* Perkins, A.C.
Hattori, S. *see* Adachi, K.
Hau Leung So, W. *see* Chun Yu Wong, B.
Hawkes, N.D., Richardson, C., Ch'ng, C.L., Green, J.T., Evans, B.K., Williams, J., Rhodes, P., Rhodes, J., Swift, G.L., Thomas, G.A.O., Hawthorne, A.B., Kingham, J.G.C. & Mayberry, J.F. Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial, 1867
Hawkes, N.D., Richardson, C., Evans, B.K., Rhodes, J., Lewis, S.J. & Thomas, G.A.O. Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine, 625
Hawkey, C.J., Jackson, L., Harper, S.E., Simon, T.J., Mortensen, E. & Lines, C.R. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans, 1
Hawkey, C.J. *see* Longstreth, G.F.
Hawkey, C.J., Laine, L., Harper, S.E., Quan, H.U.I., Bolognese, J.A. & Mortensen, E. for the Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials, 1593
Hawthorne, A.B. *see* Hawkes, N.D.
Hayes, P.C. *see* Helmy, A.
Hayes, P.C. *see* Tripathi, D.
HCR-RNA levels, 551
HCV, 953
HCV-RNA, 241
healing, 227, 1585
health economics, 945
healthy subjects, 937
heartburn, 927, 1585
Heath, M. *see* Talley, N.J.
Heaton, K.W. *see* The British-Italian Gallstone Study Group
Helicobacter pylori *eradication, 813, 1047*
Helicobacter pylori, *25, 73, 81, 87, 163, 187, 195, 203, 379, 389, 395, 403, 411, 417, 423, 487, 493, 505, 513, 613, 699, 703, 707, 805, 821, 843, 851, 875, 989, 1001, 1009, 1017, 1023, 1031, 1037, 1055, 1061, 1067, 1163, 1177, 1187, 1193, 1199, 1205, 1445, 1453, 1459, 1467, 1473, 1479, 1485, 1493, 1499, 1505, 1543, 1593, 1603, 1753, 1763, 1769, 1777, 1787, 1819, 1875, 1921, 1947, 1957, 1967, 1975, 1983*
Helmy, A. & Hayes, P.C. Review article: current endoscopic therapeutic options in the management of variceal bleeding, 575
Hennessy, E. *see* Mulcahy, H.E.
hepatitis B, 1907
hepatitis C virus, 689
hepatitis C, 551

© 2001 Blackwell Science Ltd

hepatobiliary, 899
hepatocellular carcinoma, 689
hepatocyte growth factor, 989
hepatoxicity, 1627
herbal therapy, 1239
Hernandez, L.V., Gilson, I., Jacobson, J., Affi, A., Puetz, T.R. & Dindzans, V.J. Antiretroviral hepatoxicity in human immunodeficiency virus-infected patients, 1627
Herrlinger, K.R., Noftz, M.K., Fellermann, K., Schmidt, K., Steinhoff, J. & Stange, E.F. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use, 363
Hershkoviz, R. *see* Dotan, I.
Heudebert, G.R. *see* Arguedas, M.R.
Hige, S. *see* Hokari, K.
Hin Cho, C. *see* Chun Yu Wong, B.
Hirakawa, K. *see* Adachi, K.
Hirschowitz, B.I. & Haber, M.M. *Helicobacter pylori* effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole, 87
Hirschowitz, B.I., Simmons, J. & Mohnen, J. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study, 1795
histamine H_2 antagonist, 917
histology and bacterial culture, 505
HIV, 1627
Ho, S.S.S. *see* You, J.H.S.
Hodgson, H.J.F. *see* Lindsay, J.O.
Hoes, A.W. *see* Weijnen, C.F.
Hoffman, J. *see* Graham, D.Y.
Hokari, K., Sugiyama, T., Kato, M., Saito, M., Miyagishima, T., Kudo, M., Nishikawa, K., Ishizuka, J., Komatsu, Y., Mizushima, T., Kagaya, H., Hige, S., Takeda, H. & Asaka, M. Efficacy of triple therapy with rabeprazole for *Helicobacter pylori* infection and CYP2C19 genetic polymorphism, 1479
homing, 1313
Hong, J.J., Park, W. & Ehrenpreis, E.D. Review article: current therapeutic options for radiation proctopathy, 1253
Horai, Y., Kimura, M., Furuie, H., Matsuguma, K., Irie, S., Koga, Y., Nagahama, T., Murakami, M., Matsui, T., Yao, T., Urae, A. & Ishizaki, T. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes, 793
Horowitz, A. *see* Appel-Dingemanse, S.
Horowitz, M. *see* Bytzer, P.
Howden, C.W. *see* Sharma, V.K.
Hp-*negative duodenal ulcer, 821*
Hsu, P.-I., Lai, K.-H., Tseng, H.-H., Lo, G.-H., Lo, C.-C., Lin, C.-K., Cheng, J.-S., Chan, H.-H., Ku, M.-K., Peng, N.-J., Chien, E.-J., Chen, W. & Hsu, P.-N. Eradication of *Helicobacter pylori* prevents ulcer development in patients with ulcer-like functional dyspepsia, 195
Hsu, P.-N. *see* Hsu, P.-I.
Hu, F.L. *see* Wong, B.C.Y.
Hu, P.-J. *see* Chinese National Cooperative Study Group For Helicobacter Pylori
Hu, P.-J. *see* Lu, H.
Hu, W.H.C. *see* Wong, B.C.Y.
Hu, W.H.C. *see* Xia, H.H.-X.
Hui, C.K. *see* Wong, B.C.Y.
Hui, C.-K., Lai, K.-C., Yuen, M.-F., Ng, M., Lai, C.-L. & Lam, S.-K. Acute cholangitis—predictive factors for emergency ERCP, 1633
Hui, W.M. *see* Wong, B.C.Y.
Hui, Y. *see* Chan, F.K.L.
Hull, M., Beane, A., Bowen, J. & Settle, C. Methicillin-resistant *Staphylococcus aureus* infection of percutaneous endoscopic gastrostomy sites, 1883
Hulten, K. *see* Chamberlin, W.
human teratogenic potential, 483
Humphries, T.J. *see* Galmiche, J.P.
Humphries, T.J., Waldum, H.L. & Brenna, E. Letter to the Editors, 559
Hung, W.K. *see* Wong, B.C.Y.
Hunt, R.H. *see* Bell, N.
Hurenkamp, G.J.B., Grundmeijer, H.G.L.M., Van Der Ende, A., Tytgat, G.N.J., Assendelft, W.J.J. & Van Der Hulst, R.W.M. Arrest of chronic acid suppressant drug use after successful *Helicobacter pylori* eradication in patients with peptic ulcer disease: a six-month follow-up study, 1047
Hussain, F.N. *see* Trudgill, N.J.
Hussain, F.N., Ajjan, R.A., Kapur, K., Moustafa, M. & Riley, S.A. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters, 53
Hussaini, S.H. *see* Pereira, S.P.
Hwang, C. *see* Vakil, N.B.
hyperplastic gastritis, 875
hypothalamus, 1613

Iaquinto, G. *see* Manes, G.
Ierardi, E., Principi, M., Francavilla, R., Pisani, A., Rendina, M., Ingrosso, M., Guglielmi, F.W., Panella, C. & Francavilla, A. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance, 371
IgE, 439
IgG, 439
IgG2, 439
IgG4, 439
Iijima, K. *see* Koike, T.
Ike, E. *see* Goodgame, R.W.
Ikeda, S., Tamamuro, T., Hamashima, C. & Asaka, M. Evaluation of the cost-effectiveness of *Helicobacter pylori* eradication triple therapy vs. conventional therapy for ulcers in Japan, 1777
IL-10 knockout, 1219
immune suppression, 1307
immunoassay, 395
immunoblot, 423
immunohistochemistry, 1485
immunosuppressants, 371
immunosuppression, 463, 1101
immunosuppressive therapy, 1843
in vitro *susceptibility, 487*

© 2001 Blackwell Science Ltd

in vitro, *487*, *1227*, *1417*
Inauen, W. *see* Netzer, P.
indomethacin, *257*, *1827*
induction doses, *551*
infants, *595*, *1397*
inflammation, *45*, *831*, *1699*
inflammatory bowel disease, *363*, *371*, *429*, *475*, *731*, *1101*, *1219*, *1515*, *1549*, *1687*, *1699*, *1709*, *1843*
inflammatory mediators, *1115*
infliximab, *463*, *1101*, *1515*, *1639*
Ingrosso, M. *see* Ierardi, E.
inhibitor, *1837*
insulin-like growth factor-1, *181*
interferon, *129*, *241*, *689*, *953*
interferon-alpha, *551*
interleukin 1β, *2035*
interleukin-10, *1699*, *1709*, *1827*
interleukin-8, *1227*, *1271*
interleukins, *1163*
internal anal sphincter, *887*
interstitial nephritis, *1131*
intestinal anti-inflammatory activity, *2035*
intestinal metaplasia, *1467*, *1505*
intestinal microflora, *1445*
intestinal motility, *1227*
intestinal toxicity, *2009*
intestinal transit, *625*
intraarterial, *1527*
intraepithelial lymphocytes, *1301*
intragastric acidity, *1579*
intragastric pH, *647*, *793*, *1937*
intraperitoneal, *1527*
intraportal, *1527*
intravenous, *1807*
Invernizzi, P. *see* Battezzati, P.M.
Iran, *411*
Irie, S. *see* Horai, Y.
iron deficiency anaemia, *1753*
iron, *429*, *1997*
irritable bowel syndrome, *277*, *355*, *439*, *959*, *1655*
ischaemia, *1867*
ischaemic heart disease, *1055*
Ishihara, S. *see* Adachi, K.
Ishihara, S., Okuyama, T., Ishimura, N., Ono, M., Hashimoto, T., Kazumori, H., Kaji, T., Sato, H., Fujishiro, H., Adachi, K., Fukuda, R. & Kinoshita, Y. Intragastric distribution of *Helicobacter pylori* during short-term omeprazole therapy: study using Carnoy's fixation and immunohistochemistry for detection of bacteria, 1485
Ishii, H. *see* Suzuki, H.
Ishimura, N. *see* Adachi, K.
Ishimura, N. *see* Ishihara, S.
Ishizaki, T. *see* Horai, Y.
Ishizaki, T. *see* Shirai, N.
Ishizuka, J. *see* Hokari, K.
Israel, D.A. & Peek, R.M. Review article: pathogenesis of *Helicobacter pylori*-induced gastric inflammation, 1271
Ito, Y. *see* Azuma, T.
Itoh, M. *see* Oshima, T.

Jackson, L. *see* Hawkey, C.J.
Jacob, M., Bjarnason, I., Rafi, S., Wigglesworth, J. & Simpson, R.J. A study of the effects of indomethacin on liver mitochondria from rats, mice and humans, 1837
Jacobson, J. *see* Hernandez, L.V.
Jacqz-Aigrain, E. *see* Faure, C.
Jansen, J.B.M.J. *see* Janssen, M.J.R.
Jansen, J.B.M.J. *see* Laheij, R.J.F.
Janssen, M.J.R., Van Oijen, A.H.A.M., Verbeek, A.L.M., Jansen, J.B.M.J. & De Boer, W.A. A systematic comparison of triple therapies for treatment of *Helicobacter pylori* infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole, 613
Japan, *1777*
Jazrawi, R.P. *see* The British-Italian Gallstone Study Group
Jennings, D.E. *see* Bell, N.
Jensen, R.T. *see* Corleto, V.D.
Jewell, D.P. *see* Ahmad, T.
Jewell, D.P. *see* Parkes, M.
Jirillo, E. *see* Cozzolongo, R.
Joh, T. *see* Oshima, T.
Johnson, D.A. *see* Vakil, N.B.
Johnston, D.A. *see* Todd, J.A.
Jones, M. *see* Talley, N.J.
Jones, M.P. *see* Bytzer, P.
Jones, R. & Bytzer, P. Review article: acid suppression in the management of gastro-oesophageal reflux disease—an appraisal of treatment options in primary care, 765
Jones, R.H. *see* Longstreth, G.F.
Jonkers, D. *see* Sanduleanu, S.
Jordan, P. *see* Oshima, T.
Jordinson, M. *see* Fitzgerald, A.J.
Juan, D. *see* Perkins, A.C.
Junghard, O. *see* Talley, N.J.
Justin, T. *see* Smith, A.M.

Kafwembe, E. *see* Kelly, P.
Kagaya, H. *see* Hokari, K.
Kai, A. *see* Suzuki, H.
Kaji, T. *see* Adachi, K.
Kaji, T. *see* Ishihara, S.
Kamberoglou, D., Polymeros, D., Sanidas, I., Doulgeroglou, V., Savva, S., Patra, E. & Tzias, V. Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for *Helicobacter pylori* eradication, 1493
Kamm, M.A. *see* Norton, C.
Kamm, M.A. *see* Van Den Bogaerde, J.
Kaplan, G. *see* Beaugerie, L.
Kapur, K. *see* Hussain, F.N.
Karczewska, E. *see* Konturek, P.C.
Karmeli, F. *see* Dotan, I.
Karol, M.D. *see* Bell, N.
Kato, K. *see* Koike, T.
Kato, M. *see* Hokari, K.
Kato, T. *see* Azuma, T.

© 2001 Blackwell Science Ltd

Katz, P.O. *see* Srinivasan, R.
Katz, P.O. *see* Xue, S.
Katz, P.O., Xue, S. & Castell, D.O. Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg, 647
Katzka, D.A. *see* Srinivasan, R.
Kawamura, A. *see* Adachi, K.
Kazumori, H. *see* Ishihara, S.
Keeling, P.W.N. *see* Dinan, T.G.
Kelly, A. *see* Williams, D.
Kelly, P., Musuku, J., Kafwembe, E., Libby, G., Zulu, I., Murphy, J. & Farthing, M.J.G. Impaired bioavailability of vitamin A in adults and children with persistent diarrhoea in Zambia, 973
Kendall, C. *see* Barr, H.
Kenet, G. *see* Shirin, H.
Khan Shaghaghi, E. *see* Faure, C.
Khatibian, M. *see* Fakheri, H.
Kiely, B. *see* O'Mahony, L.
Kimball, K. *see* Goodgame, R.W.
Kimura, M. *see* Horai, Y.
Kingham, J.G.C. *see* Hawkes, N.D.
Kinoshita, Y. *see* Adachi, K.
Kinoshita, Y. *see* Ishihara, S.
Klein, P.D. *see* Shiotani, A.
Kleoudis, C. *see* Talley, N.J.
Knight, S.C. *see* Van Den Bogaerde, J.
Knobler, R. *see* Reinisch, W.
Kobayashi, K. *see* Shirai, N.
Koga, Y. *see* Horai, Y.
Koike, T., Ohara, S., Sekine, H., Iijima, K., Kato, K., Toyota, T. & Shimosegawa, T. Increased gastric acid secretion after *Helicobacter pylori* eradication may be a factor for developing reflux oesophagitis, 813
Komatsu, Y. *see* Hokari, K.
Koningsberger, J.C. *see* Oldenburg, B.
Konturek, J.W. *see* Pohle, T.
Konturek, P.C., Konturek, S.J., Sulekova, Z., Meixner, H., Bielanski, W., Starzynska, T., Karczewska, E., Marlicz, K., Stachura, J. & Hahn, E.G. Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis-related proteins Bax and Bcl-2, and gastrin in human gastric cancer, 989
Konturek, S.J. Letter to the Editors, 727
Konturek, S.J. *see* Konturek, P.C.
Konturek, S.J. *see* Pohle, T.
Koppeschaar, H.P.F. *see* Moschetta, A.
Kosuge, K. *see* Shirai, N.
Kouroumalis, E. *see* Matrella, E.
Kovacs, T. *see* Vakil, N.B.
Krebs, S. *see* Dormann, H.
Križman, I. *see* Tepeš, B.
Ku, M.-K. *see* Hsu, P.-I.
Kudo, M. *see* Hokari, K.
Kuipers, E.J. *see* Weijnen, C.F.
Kulig, M. *see* Leodolter, A.
Kum Lam, S. *see* Chun Yu Wong, B.
Kumar, D. *see* Zar, S.
Kung, N.N.S. *see* Wong, B.C.Y.
Kung, N.N.S. *see* You, J.H.S.
Kuriyama, M. *see* Azuma, T.
Kurosawa, A. *see* Nagahara, A.
Kusunoki, H. *see* Nogi, K.
Kwon, D.H. *see* Graham, D.Y.

La Rovere, L. *see* Bortolotti, M.
Labayen, I., Forga, L., González, A., Lenoir-Wijnkoop, I., Nutr, R. & Martínez, J.A. Relationship between lactose digestion, gastrointestinal transit time and symptoms in lactose malabsorbers after dairy consumption, 543
lactation, 1699
Lactobacillus GG, *163*
Lactobacillus, *11*
lactose malabsorbtion, 543
Laheij, R.J.F., Jansen, J.B.M.J., Verbeek, A.L.M. & Verheugt, F.W.A. *Helicobacter pylori* infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease, 1055
Lahner, E *see* Capurso, G.
Lai, A.C.W. *see* Chan, F.K.L.
Lai, A.C.W. *see* Wu, J.C.Y.
Lai, C.-L. *see* Hui, C.-K.
Lai, K.-C. *see* Hui, C.-K.
Lai, K.C. *see* Wong, B.C.Y.
Lai, K.C. *see* Xia, H.H.-X.
Lai, K.-H. *see* Hsu, P.-I.
Lai, S.T. *see* Tsang, S.W.C.
Laine, L. Letter to the Editors, 1085
Laine, L. *see* Hawkey, C.J.
Lam, S.-K. *see* Hui, C.-K.
Lam, S.K. *see* Wong, B.C.Y.
Lam, S.K. *see* Wong, W.M.
Lam, S.K. *see* Xia, H.H.-X.
Lamarque, D. *see* Tankovic, J.
Lamb, E.J. *see* Fraser, J.S.
lamivudine, 1737
Lander, T.D. *see* Curry, J.I.
Langmead, L. & Rampton, D.S. Review article: herbal treatment in gastrointestinal and liver disease—benefits and dangers, 1239
lansoprazole, 87, 105, 227, 647, 1187, 1397, 1555, 1807, 1819
Lanzini, A. *see* The British-Italian Gallstone Study Group
Lascar, R. *see* Fitzgerald, R.C.
Lascols, C. *see* Tankovic, J.
laser, 311
Lau, G.K.K. *see* Wong, B.C.Y.
Lau, P. *see* Wong, B.C.Y.
Laurence, M. *see* Faure, C.
Laurent, J., Mégraud, F., Fléjou, J.F., Caekaert, A. & Barthélemy, P. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of *Helicobacter pylori* in patients with non-ulcer dyspepsia, 1787
Lauritsen, K. *see* Talley, N.J.
laxatives, 749
L-*carnosine*, 715
Leandro, G. *see* Pilotto, A.
Leclair, M.-D. *see* Plattner, V.

© 2001 Blackwell Science Ltd

lectin, 1077
Lee, C. *see* You, J.H.S.
Lee, C.C. *see* Szeto, M.L.
Lee, C.K. *see* Szeto, M.L.
Lee, G. *see* O'Mahony, L.
Lee, K.K.C. *see* You, J.H.S.
Lee, T.L. *see* Chan, F.K.L.
Lee, T.L. *see* To, K.F.
Lee, W.K. *see* Szeto, M.L.
Lee, Y.T. *see* Chan, F.K.L.
Lella, F. *see* Testoni, P.A.
Lenoir-Wijnkoop, I. *see* Labayen, I.
Leodolter, A., Kulig, M., Brasch, H., Meyer-Sabellek, W., Willich, S.N. & Malfertheiner, P. A meta-analysis comparing eradication, healing and relapse rates in patients with *Helicobacter pylori*-associated gastric or duodenal ulcer, 1957
Leontiadis, G.I. *see* Sharma, V.K.
Leray, V. *see* Plattner, V.
LES pressure, 233
leukocyte infiltration, 715
leukotriene B_4, 2035
Leung, N.W.Y. *see* Tsang, S.W.C.
Leung, S.Y. *see* Wong, B.C.Y.
Leung, W.K. *see* Chan, F.K.L.
Leung, W.-K. *see* Wu, J.C.Y.
Leung, W.K. *see* Yu, J.
Leung, W.K., Chow, T.P., Ng, E.K.W., Chan, F.K.L., Chung, S.C.S. & Sung, J.J.Y. Validation of a new immunoblot assay for the diagnosis of *Helicobacter pylori* in an Asian population, 423
Leung, W.K., Yu, J., To, K.F., Go, M.Y.Y., Ma, P.K., Chan, F.K.L. & Sung, J.J.Y. Apoptosis and proliferation in *Helicobacter pylori*-associated gastric intestinal metaplasia, 1467
Levi, M. *see* Vreeburg, E.M.
Levy, M. *see* Dormann, H.
Lewis, S.J. *see* Hawkes, N.D.
Lewis, S.J. *see* Wingate, D.
Li, K.F. *see* Szeto, M.L.
Li, K.F. *see* Wong, B.C.Y.
Li, T.M. *see* Wong, W.M.
Li, Y., Shin, V.Y., Cheuk, C.Y., Liu, E.S.L. & Cho, C.H. A 3.0-kDa low molecular weight heparin promotes gastric ulcer healing in rats, 2017
Li, Z. *see* Perkins, A.C.
Li, Z.-S. *see* Lu, H.
Libby, G. *see* Kelly, P.
Lieberman, D. *see* Fennerty, M.B.
Lin, C.-K. *see* Hsu, P.-I.
Lind, T. *see* Edwards, S.J.
Lind, T. *see* Talley, N.J.
Lindsay, J.O. & Hodgson, H.J.F. Review article: the immunoregulatory cytokine interleukin-10—a therapy for Crohn's disease?, 1709
Lines, C.R. *see* Hawkey, C.J.
Lioniello, M. *see* Manes, G.
lipid peroxidation, 715
Liu, E.S.L. *see* Li, Y.
Liu, W.-Z. *see* Chinese National Cooperative Study Group For Helicobacter Pylori
Liu, X.G. *see* Wong, B.C.Y.
Liu, Z. *see* Colpaert, S.
liver cirrhosis, 1975
Lo, C.-C. *see* Hsu, P.-I.
Lo, G.-H. *see* Hsu, P.-I.
Lobo, A.J. *see* Green, J.R.B.
Lobo, A.J. *see* Parsons, H.K.
Löftberg, R. *see* Blomqvist, P.
Logan, R. *see* Neal, K.
Logan, R.P.H. *see* Bebb, J.R.
Lomazzi, A. *see* Testoni, P.A.
Long, P. *see* Perkins, A.C.
Longstreth, G.F., Hawkey, C.J., Mayer, E.A., Jones, R.H., Naesdal, J., Wilson, I.K., Peacock, R.A. & Wiklund, I.K. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials, 959
long-term outcome, 1427
López, T. *see* Calvet, X.
Lopilato, C. *see* Bortolotti, M.
Lorenzetti, R. *see* Zullo, A.
Lorf, T. *see* Schwörer, H.
low molecular weight heparin, 1687, 2017
lower oesophageal sphincter, 1357, 1921
loxiglumide, 1357
Lu, H., Zhang, D.-Z., Hu, P.-J., Li, Z.-S., Lu, X.-H., Fang, X.-C. & Xiao, S.-D. One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate *Helicobacter pylori*: a multicentre, randomized, double-blind study, 1983
Lu, X.-H. *see* Lu, H.
Lüchinger, S. *see* Degen, L.
Lukasik, N.L. *see* Täubel, J.J.
Lundell, L. *see* Edwards, S.J.
Lundin, P., Naber, T., Nilsson, M. & Edsbäcker, S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease, 45
lymphatic vessel, 1115
lymphocyte proliferation, 1647
lymphocytic colitis, 1301
lymphoma, 1101, 1699

Ma, P.K. *see* Leung, W.K.
Macdonald, T.M. *see* Todd, J.A.
macrolides, 487
Maecke, H. *see* Degen, L.
Mahmud, N. *see* Dinan, T.G.
maintenance acid suppression therapy, 1047
Makino, I. *see* Hasegawa, T.
Malagelada, J.-R. *see* Wingate, D.
Malekzadeh, R. *see* Fakheri, H.
Malekzadeh, R. *see* Mikaeli, J.
Malfatti, F. *see* Giannini, E.
Malfertheiner, P. *see* Bühling, A.
Malfertheiner, P. *see* Leodolter, A.
Malfertheiner, P. *see* Yu, J.

© 2001 Blackwell Science Ltd

Maltinti, G. *see* Costa, F.
Man Wong, W. *see* Chun Yu Wong, B.
Man Yee Fung, F. *see* Chun Yu Wong, B.
management, 575
Manas, K. *see* Oshima, T.
Mandir, N. *see* Sasaki, M.
Manes, G., Balzano, A., Iaquinto, G., Ricci, C., Piccirillo, M.M., Giardullo, N., Todisco, A., Lioniello, M. & Vaira, D. Accuracy of the stool antigen test in the diagnosis of *Helicobacter pylori* infection before treatment and in patients on omeprazole therapy, 73
Manesis, E.K. *see* Hadziyannis, A.S.
Mangel, A.W. *see* Talley, N.J.
Manghetti, M. *see* Costa, F.
Manghisi, O.G. *see* Cozzolongo, R.
manometry, 157
Mansfield, J.C. *see* Aithal, G.P.
Marcheggiano, A. *see* Capurso, G.
Marchi, S. *see* Costa, F.
Marcuard, S.P. *see* Talley, N.J.
Margaret, N. *see* Fennerty, M.B.
Mari, C. *see* Bortolotti, M.
Marinello, D. *see* Oderda, G.
Markmann, A. *see* Pohle, T.
Marlicz, K. *see* Konturek, P.C.
Marshall, R. *see* Green, J.
Martínez, J.A. *see* Labayen, I.
Martínez, J.L. *see* Calleja, J.L.
Martino, G. *see* Capurso, G.
Marx, J.J.M. *see* Oldenburg, B.
Masala, G. *see* Bazzoli, F.
Massarrat, S. *see* Fakheri, H.
mast cells, 439
Matrella, E., Valatas, V., Notas, G., Roumpaki, H., Xidakis, C., Hadzidakis, A., Mouzas, I. & Kouroumalis, E. Bolus somatostatin but not octreotide reduces hepatic sinusoidal pressure by a NO-independent mechanism in chronic liver disease, 857
Matsuguma, K. *see* Horai, Y.
Matsui, T. *see* Horai, Y.
Matsuyama, K. *see* Naito, Y.
Matzinger, D. *see* Degen, L.
Mayberry, J.F. *see* Hawkes, N.D.
Mayer, E.A. *see* Longstreth, G.F.
McCormack, G., O'Donoghue, D. & Baird, A. *In-vitro* cyclosporin sensitivity of proliferating lymphocytes is predictive of *in-vivo* therapeutic response in ulcerative colitis, 665
McDonald, D. *see* Arnott, I.D.R.
McGovern, D. *see* Ahmad, T.
McKirdy, H. *see* Green, J.
McLeod, J. *see* Appel-Dingemanse, S.
McMillan, T. *see* Selvasekar, C.R.
medical decision analysis, 1403
medical diagnostics, 1403
Medline review, 887
Mégraud, F. *see* Laurent, J.
MEGX test, 1975
Meier, R., Wettstein, A., Drewe, J. & Geiser, H.R. The Swiss Helicobacter-Study Group. Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for *Helicobacter pylori* eradication, 851
Meixner, H. *see* Konturek, P.C.
Merat, S. *see* Fakheri, H.
Merz, M. *see* Degen, L.
mesalazine, 53, 1549
meta-analysis, 227, 355, 917, 1291, 1907, 1957
methotrexate, 35
metronidazole resistance, 411
metronidazole, 403, 513, 851, 1409, 1445, 1493
Metz, D.C., Buchanan, M., Purich, E. & Fein, S. A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger–Ellison Syndrome, 669
Meucci, G. *see* Vecchi, M.
Meunier, A. *see* Bruley Des Varannes, S.
Meyer-Sabellek, W. *see* Leodolter, A.
Michaeli, D. *see* Smith, A.M.
Michaud, L. *see* Faure, C.
microcirculation, 715
microscopic colitis, 1301
Miglioli, M. *see* Bortolotti, M.
Mikaeli, J., Fazel, A., Montazeri, G., Yaghoobi, M. & Malekzadeh, R. Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia, 1389
Miller-Larsson, A., Gustafsson, B., Persson, C.G.A. & Brattsand, R. Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat, 2027
Miner Jr, P.B. *see* Robinson, M.
minocycline, 487
Minoli, G. *see* Testoni, P.A.
misoprostol, 19
Mitchell, T.R. *see* Bardhan, K.D.
Miura, S. *see* Suzuki, H.
Miwa, H. *see* Nagahara, A.
Miyagishima, T. *see* Hokari, K.
Miyazawa, M. *see* Suzuki, H.
Mizoguchi, H., Hase, S., Tanaka, A. & Takeuchi, K. Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats, 257
Mizushima, T. *see* Hokari, K.
Mo Hiu, W. *see* Chun Yu Wong, B.
Mohnen, J. *see* Hirschowitz, B.I.
molecular biology, 1087
molecular rationale, 451
Moniczewski, A. *see* Pohle, T.
monoclonal antibodies, 1515
Montalto, G. *see* Carroccio, A.
Montazeri, G. *see* Mikaeli, J.
Morales, C.P. *see* Souza, R.F.
Moreno, R. *see* Calleja, J.L.
Mori, M. *see* Suzuki, H.
morin, 2035
Morini, S. *see* Zullo, A.

© 2001 Blackwell Science Ltd

Moriyama, Y. *see* Shirai, N.
Morris, P. *see* Bardhan, K.D.
Morris, T. *see* Smith, A.M.
Mortensen, E. *see* Hawkey, C.J.
Mortensen, N.J.McC. *see* Cook, T.A.
Morton, D. *see* Bardhan, K.D.
Moschetta, A., Stolk, M.F.J., Rehfeld, J.F., Portincasa, P., Slee, P.H.TH.J., Koppeschaar, H.P.F., Van Erpecum, K.J. & Vanberge-Henegouwen, G.P. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during sandostatin LAR, 181
Moser, G. *see* Reinisch, W.
Moss, S.F. *see* Shirin, H.
motility, 653
Mougenot, J.F. *see* Faure, C.
Moum, B. *see* Talley, N.J.
Moustafa, M. *see* Hussain, F.N.
Moustafa, M. *see* Trudgill, N.J.
Mouzas, I. *see* Matrella, E.
Mowat, C. & Stanley, A.J. Review article: spontaneous bacterial peritonitis—diagnosis, treatment and prevention, 1851
MRSA, 1883
mucosa, 539
mucosal permeability, 11
Mulcahy, H.E., Hennessy, E., Connor, P., Rhodes, B., Patchett, S.E., Farthing, M.J.G. & Fairclough, P.D. Changing patterns of sedation use for routine out-patient diagnostic gastroscopy between 1989 and 1998, 217
Mulder, C.J.J. *see* Geboes, K.
Muller, A.F. *see* Fraser, J.S.
Müller, W.A. *see* Bühling, A.
Müller-Lissner, S.A., Fumagalli, I., Bardhan, K.D., Pace, F., Pecher, E., Nault, B. & Rüegg, P. Tegaserod, a 5-HT_4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation, 1655
Mumolo, M.G. *see* Costa, F.
Murakami, M. *see* Horai, Y.
Muramatsu, A. *see* Azuma, T.
Murphy, G.M. *see* Pereira, S.P.
Murphy, J. *see* Kelly, P.
Murphy, L. *see* O'Mahony, L.
Musuku, J. *see* Kelly, P.
Muth-Selbach, U. *see* Dormann, H.
mycobacteria, 337, 1861

Naber, T. *see* Lundin, P.
nabumetone, 19, 539, 2009
Naesdal, J. *see* Dinan, T.G.
Naesdal, J. *see* Longstreth, G.F.
Nagahama, T. *see* Horai, Y.
Nagahara, A., Miwa, H., Yamada, T., Kurosawa, A., Ohkura, R. & Sato, N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for *Helicobacter pylori* infection, 417
Nahavandi, H. *see* Reinisch, W.
Naito, Y., Takagi, T., Matsuyama, K., Yoshida, N. & Yoshikawa, T. Pioglitazone, a specific PPAR-γ ligand, inhibits aspirin-induced gastric mucosal injury in rats, 865
Nakagawa, K. *see* Shirai, N.
Nakamura, K. *see* Hasegawa, T.
naloxone, 625
Naser, S. *see* Chamberlin, W.
Natale, C. *see* Testoni, P.A.
Nault, B. *see* Müller-Lissner, S.A.
Navarro, J. *see* Faure, C.
Neal, K. & Logan, R. Letter to the Editors, 1085
neoplasia, 1699
nephrotoxicity, 363
Netzer, P., Domek, M., Pai, R., Halter, F. & Tarnawski, A. Inhibition of human colon cancer cell growth by antisense oligodeoxynucleotides targeted at basic fibroblast growth factor, 1673
Netzer, P., Gut, A., Brundler, R., Gaia, C., Halter, F. & Inauen, W. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis, 1375
neutrophil, 865
Newman, D.J. *see* Fraser, J.S.
NF-κB, 1211
Ng, E.K.W. *see* Leung, W.K.
Ng, E.K.W. *see* Yu, J.
Ng, M. *see* Hui, C.-K.
Ng, Y.P. *see* Chan, F.K.L.
Ng, Y.P. *see* To, K.F.
Nicolini, G. *see* Bazzoli, F.
nicotine, 653
Nielsen, O.H., Vainer, D. & Rask-Madsen, J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine, 1699
Niigaki, M. *see* Adachi, K.
Nilsson, M. *see* Lundin, P.
Niro, G.A. *see* Perri, F.
Nishikawa, K. *see* Hokari, K.
nitazoxanide, 1409
nitric oxide synthase, 2035
nitric oxide, 157, 857, 1867
nitrofurantoin, 513
nitroimidazole, 613
Niv, Y. *see* Shirin, H.
nizatidine, 1291, 1571
nocturnal gastric acid breakthrough, 1351
Noftz, M.K. *see* Herrlinger, K.R.
Nogi, K., Haruma, K., Taniguchi, H., Yomota, E., Okajima, M., Hanaoki, M., Hata, J., Kusunoki, H. & Onoda, Y. Duodenogastric reflux following cholecystectomy in the dog: role of antroduodenal motor function, 1233
nonalcoholic steatohepatitis, 1667
non-Helicobacter pylori bacteria, 379
non-Helicobacter pylori bacterial flora, 1163
non-Hodgkin's lymphoma, 1843
non-responders, 953
non-ulcer dyspepsia, 805, 1177, 1291, 1493, 1603, 1613
NO-releasing indomethacin (NCX-530), 257

© 2001 Blackwell Science Ltd

Nørgård, B., Czeizel, A.E., Rockenbauer, M., Olsen, J. & Sørensen, H.T. Population-based case control study of the safety of sulfasalazine use during pregnancy, 483
Northfield, T.C. *see* The British-Italian Gallstone Study Group
Norton, C. & Kamm, M.A. Anal sphincter biofeedback and pelvic floor exercises for faecal incontinence in adults—a systematic review, 1147
Notarbartolo, A. *see* Carroccio, A.
Notas, G. *see* Matrella, E.
NSAIDs, 1, 11, 19, 25, 63, 1301, 1593, 1837, 1875, 2009
Numans, M.E. *see* Weijnen, C.F.
Nusteling, K. *see* Geboes, K.
Nutr, R. *see* Labayen, I.
nutrient malabsorption, 1619

O'Donoghue, D. *see* McCormack, G.
O'Halloran, S. *see* O'Mahony, L.
O'Kelly, P. *see* Williams, D.
O'Mahony, L., Feeney, M., O'Halloran, S., Murphy, L., Kiely, B., Fitzgibbon, J., Lee, G., O'Sullivan, G., Shanahan, F. & Collins, J.K. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice, 1219
O'Morain, C.A. *see* Dinan, T.G.
O'Sullivan, G. *see* O'Mahony, L.
Oberhuber, G. *see* Vogelsang, H.
octreotide, 181, 857, 965, 1435, 1889
Oderda, G., Rapa, A., Marinello, D., Ronchi, B. & Zavallone, A. Usefulness of *Helicobacter pylori* stool antigen test to monitor resonse to eradication in children, 203
oedema, 1115
oesophageal manometry, 1921
oesophageal motility, 1375
oesophageal pH monitoring, 151
oesophageal transit, 115
oesophagitis, 221, 227, 1375
Ohara, S. *see* Koike, T.
Ohashi, K. *see* Shirai, N.
Ohkura, R. *see* Nagahara, A.
Ohtani, M. *see* Azuma, T.
Ojetti, V. *see* Armuzzi, A.
Ojetti, V. *see* Canducci, F.
Okajima, M. *see* Nogi, K.
Okochi, H. *see* Shirai, N.
Okuyama, T. *see* Ishihara, S.
Oldenburg, B., Koningsberger, J.C., Van Berge Henegouwen, G.P., Van Asbeck, B.S. & Marx, J.J.M. Review article: iron and inflammatory bowel disease, 429
Olsen, J. *see* Nørgård, B.
omeprazole, 73, 227, 647, 927, 1343, 1445, 1485, 1555, 1563, 1585, 1787, 1937
Omland, T.M. *see* Talley, N.J.
on-demand therapy, 347
one-week regimens, 1983
Ono, M. *see* Ishihara, S.
Onoda, Y. *see* Nogi, K.
opioid, 625
oral hypoglycaemic drugs, 137
oral mesalazine, 251
oral rehydration, 773
Orel, I. *see* Tepeš, B.
orocoecal transit time, 543
oropharynx, 899
Orr, W.C., Chen, C.-L. & Sloan, S. The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease, 1385
Ortiz, J.J., Ayoub, A., Gargala, G., Chegne, N.L. & Favennec, L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru, 1409
Osato, M.S. *see* Graham, D.Y.
Osato, M.S. *see* Shiotani, A.
Osato, M.S., Reddy, S.G., Piergies, A.A., Bochenek, W.J., Testa, R.T. & Graham, D.Y. Comparative efficacy of new investigational agents against *Helicobacter pylori*, 487
Osborn, J. *see* Capurso, G.
Osborne, S. *see* Appel-Dingemanse, S.
Osborne, S. *see* Degen, L.
Oshima, T., Pavlick, K., Grisham, M.B., Jordan, P., Manas, K., Joh, T., Itoh, M. & Alexander, J.S. Glucocorticoids and IL-10, but not 6-MP, 5-ASA or sulfasalazine block endothelial expression of MAdCAM-1: implications for inflammatory bowel disease therapy, 1211
osteoarthritis, 1
osteopenia, 783
osteoporosis, 783
Ou, C.-N. *see* Goodgame, R.W.
outcome research, 1403
Ouyang, Q. *see* Chinese National Cooperative Study Group For Helicobacter Pylori
over-the-counter drugs, 1263
oxidative phosphorylation, 1837
oxidative stress, 1997

p27, 1505
Pace, F. *see* Müller-Lissner, S.A.
Paci, A. *see* Costa, F.
paediatrics, 1397
Pai, R. *see* Netzer, P.
pain, 1655
Pajares, J.M. *see* Gisbert, J.P.
Palli, D. *see* Bazzoli, F.
palliation, 899
Palmer, R.H. *see* Basson, M.D.
Palmer, R.H. *see* Tibble, J.
Pan, W.J. *see* Täubel, J.J.
pancreatic insufficiency, 1619
Panella, C. *see* Ierardi, E.
pantoprazole, 851, 1023, 1031, 1375, 1585, 1807, 1929
Panuccio, D. *see* Bazzoli, F.
Panzini, L. *see* Basson, M.D.
Papadimitropoulos, V.C. *see* Papatheodoridis, G.V.
Papaioannou, C. *see* Hadziyannis, A.S.
Papatheodoridis, G.V., Papadimitropoulos, V.C. & Hadziyannis, S.J. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis, 689

© 2001 Blackwell Science Ltd

parallel-group comparison, 1585
parental therapy, 35
parenteral nutrition, 1077
Parisi, P. *see* Di Marco, V.
Park, W. *see* Hong, J.J.
Parkes, M. & Jewell, D.P. Review article: the management of severe Crohn's disease, 563
Parsons, H.K., Carter, M.J., Saunders, D.S., Winstanley, T. & Lobo, A.J. *Helicobacter pylori* antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status, 1473
partial agonist, 277
pasteurisation, 543
Patchett, S.E. *see* Mulcahy, H.E.
patient recruitment, 959
Patra, E. *see* Kamberoglou, D.
Paul, K., Redman, C.M. & Chen, M. Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn, 1571
Pavlick, K. *see* Oshima, T.
Pazzi, P. *see* The British-Italian Gallstone Study Group
Peacock, R.A. *see* Longstreth, G.F.
peak acid output, 1563
Pecher, E. *see* Müller-Lissner, S.A.
Peek, R.M. *see* Israel, D.A.
Pehl, C., Pfeiffer, A., Waizenhoefer, A., Wendl, B. & Schepp, W. Effect of caloric density of a meal on lower oesophageal sphincter motility and gastro-oesophageal reflux in healthy subjects, 233
Peled, Y. *see* Dotan, I.
pelvic floor exercises, 1147
pelvic malignancies, 1253
Peng, N.-J. *see* Hsu, P.-I.
pepsin secretion, 1795
peptic ulcer bleeding, 639
peptic ulcer disease, 1047
peptic ulcer, 195, 917
Pepto-Bismol, 513
Peralta, S. *see* Di Marco, V.
perception, 1929
percutaneous endoscopic gastrostomy, 1883
Pereira, S.P., Hussaini, S.H., Murphy, G.M., Wass, J.A.H. & Dowling, R.H. Octreotide increases the proportions of arachidonic acid-rich phospholipids in gall-bladder bile, 1435
peripheral blood mononuclear cell, 665
Perkins, A.C., Wilson, C.G., Frier, M., Blackshaw, P.E., Juan, D., Dansereau, R.J., Hathaway, S., Li, Z., Long, P. & Spiller, R.C. Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastrooesophageal reflux disease and normal control subjects, 115
permeability, 1417, 1861
Perri, F., Villani, M.R., Festa, V., Quitadamo, M. & Andriulli, A. Predictors of failure of *Helicobacter pylori* eradication with the standard 'Maastricht triple therapy', 1023
Perri, F., Villani, M.R., Quitadamo, M., Annese, V., Niro, G.A. & Andriulli, A. Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?, 1017
Perry, M.J. *see* Bardhan, K.D.
Perschy, T. *see* Talley, N.J.
persistent diarrhoea, 973
Persson, C.G.A. *see* Miller-Larsson, A.
Petroni, M.L. *see* The British-Italian Gallstone Study Group
Pfeiffer, A. *see* Pehl, C.
pH monitoring, 519, 1155
pH, 1763
pharmacodynamics, 1807
pharmacoepidemiology, 171
pharmacokinetic disposition, 1937
pharmacokinetics, 53, 105, 793, 937, 1745, 1807
pharmacovigilance, 171
phenothiazines, 1915
Phillips, S.F. *see* Wingate, D.
phospholipids, 1435
photodynamic therapy, 899
photodynamic, 311
Piccirillo, M.M. *see* Manes, G.
Piergies, A.A. *see* Osato, M.S.
Pigozzi, M.G. *see* The British-Italian Gallstone Study Group
Pilmer, B.L. *see* Täubel, J.J.
Pilotto, A., Franceschi, M., Leandro, G., Bozzola, L., Rassu, M., Soffiati, G., Di Mario, F. & Valerio, G. Cure of *Helicobacter pylori* infection in elderly subjects: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole, 1031
Ping Wang, W. *see* Chun Yu Wong, B.
pioglitazone, 865
Pisani, A. *see* Ierardi, E.
Platt, I. *see* Carrier, J.
Plattner, V., Leray, V., Leclair, M.-D., Aubé, A.-C., Cherbut, C. & Galmiche, J.P. Interleukin-8 increases acetylcholine response of rat intestinal segments, 1227
Plevy, S.E. *see* Cornillie, F.
pneumatic dilatation, 1389
Podda, M. *see* Battezzati, P.M.
Podda, M. *see* The British-Italian Gallstone Study Group
Pohle, T., Brzozowski, T., Becker, J.C., Van Der Voort, I.R., Markmann, A., Konturek, S.J., Moniczewski, A., Domschke, W. & Konturek, J.W. Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C, 677
Pola, P. *see* Armuzzi, A.
Pola, P. *see* Canducci, F.
Polegato, S. *see* Giannini, E.
polymerase chain reaction, 505
Polymeros, D. *see* Kamberoglou, D.
Popon, M. *see* Faure, C.
population-based study, 1001
portal hypertension, 291, 857
Portincasa, P. *see* Moschetta, A.
Porto, D. *see* Zullo, A.
post-ERCP pancreatitis, 965
postprandial heartburn, 1365
Pounder, R.E. *see* Hamilton, M.I.
Poynard, T., Regimbeau, C. & Benhamou, Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, 355

© 2001 Blackwell Science Ltd

Pozzato, P. *see* Bazzoli, F.
PPAR-γ, *865*
Prada, A. *see* Testoni, P.A.
prebiotic, *1139*
prednisolone, *2027*
pregnancy, *1699*
prevention, *323*
Prier, A. *see* Beaugerie, L.
primary biliary cirrhosis, *1427*
primary care, *1047*, *1205*, *1769*
primary prophylaxis, *291*
Principi, M. *see* Ierardi, E.
probiotic flora, *1219*
probiotic, *11*, *773*
probiotics, *163*
prognostic scoring system, *1633*
prokinetic agents, *595*, *1717*
prolactin, *1613*
proliferation, *1087*, *1467*, *2017*
prolonged antisecretory therapy, *1037*
promotile, *1745*
prophylaxis, *1851*
prostaglandin E_2, *875*
protein turnover, *105*
proteinuria, *363*
proton pump inhibitors, *81*, *105*, *269*, *347*, *513*, *613*, *647*, *765*, *917*, *927*, *1067*, *1351*, *1397*, *1555*, *1563*, *1729*, *1795*
psychiatric disorders, *1915*
Puetz, T.R. *see* Hernandez, L.V.
Purich, E. *see* Metz, D.C.
pyloric relaxation, *1233*

quadruple therapy, *417*, *1061*
quality of life, *207*
Quan, H.U.I. *see* Hawkey, C.J.
Que, T.L. *see* Szeto, M.L.
questionnaire, *207*
Quitadamo, M. *see* Perri, F.

rabeprazole, *793*, *1343*, *1479*, *1937*
Rachmilewitz, D. *see* Dotan, I.
Radespiel-Tröger, M. *see* Dormann, H.
radiation proctopathy, *1253*
Radun, D. *see* Bühling, A.
Rafi, S. *see* Jacob, M.
Ragunath, K. & Williams, J.G. Review article: balsalazide therapy in ulcerative colitis, 1549
Ramadori, G. *see* Schwörer, H.
Ramakrishnan, A. *see* Srinivasan, R.
Ramirez, H. *see* Fischbach, L.A.
Rampal, P. *see* Galmiche, J.P.
Rampton, D.S. *see* Carty, E.
Rampton, D.S. *see* Langmead, L.
randomized clinical trial, *1427*
randomized controlled crossover study, *669*
randomized controlled trial, *525*, *1867*
randomized, *1585*
ranitidine bismuth citrate, *613*, *1017*, *1193*, *1199*, *1493*, *1983*
ranitidine, *1291*, *1365*, *1579*
Rapa, A. *see* Oderda, G.
rapid urease test, *505*
Rask-Madsen, J. *see* Nielsen, O.H.
Rassu, M. *see* Pilotto, A.
rat, *1227*, *1827*, *2027*
Rathore, O. *see* Dinan, T.G.
Rauws, E.A.J. *see* Vreeburg, E.M.
reactivation, *1737*
real time results, *389*
Realpe, J.L *see* Fischbach, L.A.
rebamipide, *1603*
Reddy, S. *see* Graham, D.Y.
Reddy, S.G. *see* Osato, M.S.
Redman, C.M. *see* Paul, K.
Redstone, H.A., Barrowman, N. & Veldhuyzen Van Zanten, S.J.O. H_2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials, 1291
reflux oesophagitis, *813*, *1585*, *1729*, *1819*, *1921*
Regimbeau, C. *see* Poynard, T.
Rehfeld, J.F. *see* Moschetta, A.
Reinisch, W., Nahavandi, H., Santella, R., Zhang, Y., Gasché, C., Moser, G., Waldhör, T., Gangl, A., Vogelsang, H. & Knobler, R. Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study, 1313
reliability, *207*
relief, *1655*
remission, *1331*
renal disease, *1131*
Rendina, M. *see* Ierardi, E.
resistance, *403*, *707*
responsiveness to GERD treatment, *981*
responsiveness, *207*
resuscitation, *1109*
re-treatment, *1017*, *1193*
review, *731*, *1087*, *1699*, *1709*
Rhodes, B. *see* Mulcahy, H.E.
Rhodes, J. *see* Green, J.
Rhodes, J. *see* Hawkes, N.D.
Rhodes, J.M. *see* Fitzgerald, A.J.
Rhodes, P. *see* Hawkes, N.D.
ribavirin, *129*, *241*, *953*
Ricci, C. *see* Manes, G.
Ricciardiello, L. *see* Bazzoli, F.
Richardson, C. *see* Green, J.
Richardson, C. *see* Hawkes, N.D.
Richter, J.E. *see* Fackler, W.K.
ridogrel, *1323*
Riff, D.S. *see* Talley, N.J.
Riley, S.A. *see* Hussain, F.N.
Riley, S.A. *see* Trudgill, N.J.
Ringe, B. *see* Schwörer, H.
risedronate, *115*
Rizzetto, M. *see* Actis, G.C.
Roberts, P.M. *see* Bardhan, K.D.

© 2001 Blackwell Science Ltd

Robinson, M., Rodriguez-Stanley, S., Ciociola, A.A., Filinto, J., Zubaidi, S., Miner Jr, P.B. & Gardner, J.D. Synergy between low-dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal-induced heartburn, 1365
Rockenbauer, M. *see* Nørgård, B.
Roda, E. *see* Bazzoli, F.
Rodolico, V. *see* Di Marco, V.
Rodríguez-Cabezas, M.E. *see* Gálvez, J.
Rodriguez-Stanley, S. *see* Robinson, M.
rofecoxib, 1, 1593
Röhss, K. *see* Andersson, T.
Romagnoli, P. *see* Giannini, E.
Romano, M.R. *see* Costa, F.
Ronchi, B. *see* Oderda, G.
Roqué, M. *see* Gisbert, J.P.
Rossi, I. *see* Calleja, J.L.
Roumpaki, H. *see* Matrella, E.
Rowland, A. *see* Bardhan, K.D.
Rüegg, P. *see* Müller-Lissner, S.A.
Ruiz, B. *see* Fischbach, L.A.
Rutgeerts, P. *see* Carty, E.
Rutgeerts, P. *see* Colpaert, S.
Rutgeerts, P. *see* Cornillie, F.
Rutgeerts, P.J. Review article: the limitations of corticosteroid therapy in Crohn's disease, 1515

Sachs, G. *see* Bell, N.
Saeed, A. *see* Shiotani, A.
Saeed, M.A. *see* Graham, D.Y.
Saez, L.R. *see* Talley, N.J.
safety, 1263
Sahai, A.V. *see* Sharma, V.K.
Saito, M. *see* Hokari, K.
salivary secretion, 151
Samsom, M. *see* Schwartz, M.P.
Sandborn, W.J. *see* Coulie, B.
Sanders, D.S. *see* Bardhan, K.D.
Sanduleanu, S., Jonkers, D., De Bruïne, A., Hameeteman, W. & Stockbrügger, R.W. Non-*Helicobacter pylori* bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa, 379
Sanduleanu, S., Jonkers, D., De Bruïne, A., Hameeteman, W. & Stockbrügger, R.W. Double gastric infection with *Helicobacter pylori* and non-*Helicobacter pylori* bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis, 1163
Sanfeliu, I. *see* Calvet, X.
Sanidas, I. *see* Kamberoglou, D.
Santella, R. *see* Reinisch, W.
Sapone, N. *see* Actis, G.C.
Sasaki, K. *see* Sasaki, M.
Sasaki, M., Fitzgerald, A.J., Mandir, N., Sasaki, K., Wright, N.A. & Goodlad, R.A. Glicentin, an active enteroglucagon, has a significant trophic role on the small intestine but not on the colon in the rat, 1681
Sato, H. *see* Adachi, K.
Sato, H. *see* Ishihara, S.
Sato, N. *see* Nagahara, A.
Satsangi, J. *see* Ahmad, T.
Saunders, D.S. *see* Parsons, H.K.
Savarino, V. *see* Giannini, E.
Savary/Miller classification, 1585
Savva, S. *see* Kamberoglou, D.
Schaible, T. *see* Cornillie, F.
Scheiman, J.M., Bandekar, R.R., Chernew, M.E. & Fendrick, A.M. *Helicobacter pylori* screening for individuals requiring chronic NSAID therapy: a decision analysis, 63
Schepp, W. *see* Pehl, C.
Schiller, L.R. Review article: the therapy of constipation, 749
Schmidt, B.A. *see* Fischbach, L.A.
Schmidt, K. *see* Herrlinger, K.R.
Schneider, H. *see* Carty, E.
Schneider, T. *see* Dormann, H.
Schnell, T.G. *see* Avidan, B.
Schoon, E.J., Geerling, B.G., Van Dooren, I.M.A., Schurgers, L.J., Vermeer, C., Brummer, R.-J.M. & Stockbrügger, R.W. Abnormal bone turnover in long-standing Crohn's disease in remission, 783
Schulz, T. *see* Talley, N.J.
Schurgers, L.J. *see* Schoon, E.J.
Schwartz, H. *see* Talley, N.J.
Schwartz, M.P., Samsom, M., Van Berge Henegouwen, G.P. & Smout, A.J.P.M. Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia, 1929
Schwartz, M.R. *see* Chamberlin, W.
Schwarzenhofer, M. *see* Vogelsang, H.
Schwörer, H., Lorf, T., Ringe, B. & Ramadori, G. Letter to the Editors, 559
scintigraphy, 115
Scott, L.V. *see* Dinan, T.G.
screening, 451
secondary prophylaxis, 291
sedation, 217
Sekine, H. *see* Koike, T.
self-medication, 773
Selmi, C. *see* Battezzati, P.M.
Selvasekar, C.R., Birbeck, N., Mcmillan, T., Wainwright, M. & Walker, S.J. Review article: photodynamic therapy and the alimentary tract, 899
sensitivity, 423, 1403
Sercombe, J. *see* Hamilton, M.I.
serological tests, 703
serotonin (5-HT), 1655
serotonin, 277, 1613
Serrano, J. *see* Corleto, V.D.
serum gastrin, 105, 793
Seto, K. *see* Suzuki, H.
Settle, C. *see* Hull, M.
severe, 563
sex, 1473
Shafran, I. *see* Chamberlin, W.
Shahmurov, M. *see* Shirin, H.
Shaker, R. *see* Vakil, N.B.
Shanahan, F. *see* O'Mahony, L.

© 2001 Blackwell Science Ltd

Sharma, V.K. *see* Täubel, J.J.
Sharma, V.K., Leontiadis, G.I. & Howden, C.W. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis, 227
Sharma, V.K., Sahai, A.V., Corder, F.A. & Howden, C.W. *Helicobacter pylori* eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage, 1947
Shaw, M. *see* Fennerty, M.B.
Shaw, M.J., Beebe, T.J., Adlis, S.A. & Talley, N.J. Reliability and validity of the digestive health status instrument in samples of community, primary care, and gastroenterology patients, 981
Shealy, D. *see* Cornillie, F.
Sheen, C.L. & Colin-Jones, D.G. Review article: over-the-counter drugs and the gastrointestinal tract, 1263
Shevah, O. *see* Shirin, H.
Shimosegawa, T. *see* Koike, T.
Shin, V.Y. *see* Chun Yu Wong, B.
Shin, V.Y. *see* Li, Y.
Shiotani, A., Saeed, A., Yamaoka, Y., Osato, M.S., Klein, P.D. & Graham, D.Y. Citric acid enhanced *Helicobacter pylori* urease activity *in vivo* is unrelated to gastric emptying, 1763
Shirai, N. *see* Xiao, F.
Shirai, N., Furuta, T., Moriyama, Y., Okochi, H., Kobayashi, K., Takashima, M., Xiao, F., Kosuge, K., Nakagawa, K., Hanai, H., Chiba, K., Ohashi, K. & Ishizaki, T. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH, 1937
Shirin, H., Kenet, G., Shevah, O., Wardi, Y., Birkenfeld, S., Shahmurov, M., Bruck, R., Niv, Y., Moss, S.F. & Avni, Y. Evaluation of a novel continuous real time ^{13}C urea breath analyser for *Helicobacter pylori*, 389
Shiu Lam Liu, E. *see* Chun Yu Wong, B.
short-term therapy, 1967
Shrier, I. *see* Szilagyi, A.
side-effects, 363
Sigthorsson, G. *see* Tibble, J.
sildenafil, 157
Simmons, J. *see* Hirschowitz, B.I.
Simon, T.J. *see* Hawkey, C.J.
simplified lansoprazole suspension, 1807
Simpson, R.J. *see* Jacob, M.
Singh, R. *see* Fitzgerald, A.J.
Slee, P.H.TH.J. *see* Moschetta, A.
Sloan, S. *see* Orr, W.C.
small bowel inflammation, 1827
small intestine damage, 257
Smith, A.M., Morris, T., Justin, T., Michaeli, D. & Watson, S.A. Gastrimmune-induced antigastrin-17 antibodies inhibit acid secretion in a rat fistula model, 1989
Smith, D.J. *see* Fraser, J.S.
smooth muscle relaxants, 355
Smout, A.J.P.M. *see* Schwartz, M.P.
Snel, P. *see* Vreeburg, E.M.
socio-economic status, 1473
Soffiati, G. *see* Pilotto, A.
somatostatin, 857, 1889
Soni, A. & Sonnenberg, A. Healthcare resource utilization in the management of oesophageal adenocarcinoma, 945
Sonnenberg, A. *see* Avidan, B.
Sonnenberg, A. *see* Soni, A.
Sonnenberg, A. When William of Ockham meets Thomas Bayes: finding a few diagnoses among a great many symptoms, 1403
Sontag, S.J. *see* Avidan, B.
Sørensen, H.T. *see* Nørgård, B.
Soussy, C.J. *see* Tankovic, J.
Souza, R.F. Review article: a molecular rationale for the how, when and why of colorectal cancer screening, 451
Souza, R.F., Morales, C.P. & Spechler, S.J. Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus, 1087
Spanou, F. *see* Hadziyannis, A.S.
Spechler, S.J. *see* Souza, R.F.
specificity, 423, 1403
Speelman, P. *see* Wingate, D.
Spiller, R.C. *see* Perkins, A.C.
spontaneous bacterial peritonitis, 1851
spontaneous constriction, 1115
Srinivasan, R., Katz, P.O., Ramakrishnan, A., Katzka, D.A., Vela, M.F. & Castell, D.O. Maximal acid reflux control for Barrett's oesophagus: feasible and effective, 519
Stachura, J. *see* Konturek, P.C.
Stange, E.F. *see* Herrlinger, K.R.
Stanghellini, V. Review article: pain versus discomfort—is differentiation clinically useful?, 145
Stanghellini, V. *see* De Giorgio, R.
Stanley, A.J. *see* Mowat, C.
Starzynska, T. *see* Konturek, P.C.
steatorrhea, 1619
Steffen, R. *see* Wingate, D.
Steiner, B. *see* Vogelsang, H.
Steinhoff, J. *see* Herrlinger, K.R.
step-down treatment, 765
steroid, 1211, 2027
steroid-dependency, 1313
Stockbrügger, R.W. *see* Sanduleanu, S.
Stockbrügger, R.W. *see* Schoon, E.J.
Stolk, M.F.J. *see* Moschetta, A.
stomach, 157
Stone, N. *see* Barr, H.
stool antigen, 73, 203
stool consistency, 1655
stools, 395
Stringer, M.D. *see* Curry, J.I.
subgroup, 195
Suematsu, M. *see* Suzuki, H.
Sugiyama, T. *see* Hokari, K.
Sulekova, Z. *see* Konturek, P.C.
sulphasalazine, 483
Sung, J.J.-Y. *see* Chan, F.K.L.
Sung, J.J.-Y. *see* Chan, H.L.-Y.
Sung, J.J.Y. *see* Leung, W.K.

© 2001 Blackwell Science Ltd

Sung, J.J.Y. *see* To, K.F.
Sung, J.J.Y. *see* Tsang, S.W.C.
Sung, J.J.Y. *see* Wu, J.C.Y.
Sung, J.J.Y. *see* You, J.H.S.
Sung, J.J.Y. *see* Yu, J.
superoxide dismutase, 677
surgery, 563
surveillance colonoscopy, 631
susceptibility, 487
Suto, H. *see* Azuma, T.
Sutton, F. *see* Goodgame, R.W.
Suzuki, H., Mori, M., Seto, K., Miyazawa, M., Kai, A., Suematsu, M., Yoneta, T., Miura, S. & Ishii, H. Polaprezinc attenuates the *Helicobacter pylori*-induced gastric mucosal leukocyte activation in Mongolian gerbils—a study using intravital videomicroscopy, 715
Sweden, 475
Swift, G.L. *see* Hawkes, N.D.
symptom definition, 145
symptom relief, 1585, 1769
syndrome, 337
synthetic secretin, 669
systematic review, 1729, 1907
Szeto, M.L. *see* Wong, B.C.Y.
Szeto, M.L., Lee, C.K., Yee, Y.K., Li, K.F., Lee, W.K., Lee, C.C., Que, T.L. & Wong, B.C.Y. Evaluation of five commercial serological tests for the detection of *Helicobacter pylori* infection in Chinese, 703
Szilagyi, A. & Shrier, I. Systematic review: the use of somatostatin or octreotide in refractory diarrhoea, 1889

T cells, 1699
T helper cells, 1271
tacrolimus, 371
Takagi, T. *see* Naito, Y.
Takashima, M. *see* Shirai, N.
Takashima, M. *see* Xiao, F.
Takeda, H. *see* Hokari, K.
Takeuchi, K. *see* Mizoguchi, H.
Talley, N.J. *see* Bytzer, P.
Talley, N.J. *see* Shaw, M.J.
Talley, N.J., Lauritsen, K., Tunturi-Hihnala, H., Lind, T., Moum, B., Bang, C., Schulz, T., Omland, T.M., Delle, M. & Junghard, O. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months, 347
Talley, N.J., Riff, D.S., Schwartz, H. & Marcuard, S.P. Double-blind placebo-controlled multicenter studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without *Helicobacter pylori* infection, 1603
Talley, N.J., Van Zanten, S.V., Saez, L.R., Dukes, G., Perschy, T., Heath, M., Kleoudis, C. & Mangel, A.W. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia, 525
Talley, N.J., Verlinden, M. & Jones, M. Quality of life in functional dyspepsia: reponsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form, 207
Tam, W. *see* Chan, H.L.-Y.
Tamamuro, T. *see* Ikeda, S.
Tamborrino, V. *see* Cozzolongo, R.
Tanaka, A. *see* Mizoguchi, H.
Tang, J.-L. *see* Chan, H.L.-Y.
Tang, V.S.Y. *see* Wong, B.C.Y.
Taniguchi, H. *see* Nogi, K.
Tankovic, J., Lamarque, D., Lascols, C., Soussy, C.J. & Delchier, J.C. Impact of *Helicobacter pylori* resistance to clarithromycin on the efficacy of the omeprazole–amoxicillin–clarithromycin therapy, 707
Targan, S.R. *see* Cornillie, F.
Tarnawski, A. *see* Netzer, P.
Täubel, J.J., Sharma, V.K., Chiu, Y.L., Lukasik, N.L., Pilmer, B.L. & Pan, W.J. A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH, 1807
tegaserod, 277, 937, 1655, 1745
Ten Cate, J.W. *see* Vreeburg, E.M.
Tepeš, B., Križman, I., Gorenšek, M., Gubina, M. & Orel, I. Is a one-week course of triple anti-*Helicobacter pylori* therapy sufficient to control active duodenal ulcer?, 1037
Terano, A. *see* Hasegawa, T.
test characteristics, 1403
Testa, E. *see* Giannini, E.
Testa, R. *see* Giannini, E.
Testa, R.T. *see* Osato, M.S.
Testoni, P.A., Bagnolo, F., Andriulli, A., Bernasconi, G., Crotta, S., Lella, F., Lomazzi, A., Minoli, G., Natale, C., Prada, A., Toti, G.L. & Zambelli, A. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial, 965
test–retest reliability, 981
tetracycline, 487, 513, 831
Thakore, J. *see* Dinan, T.G.
The British-Italian Gallstone Study Group: Petroni, M.L., Jazrawi, R.P., Pazzi, P., Lanzini, A., Zuin, M., Pigozzi, M.G., Fracchia, M., Galatola, G., Alvisi, V., Heaton, K.W., Podda, M. & Northfield, T.C. Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial, 123
The Freedom Investigator Group *see* Green, J.R.B.
therapeutic strategies, 575
therapy, 403, 665, 749, 1453, 1493
thioguanine nucleotides, 1699
thiopurine-S-methyltransferase, 1699
Thomas, G. *see* Green, J.
Thomas, G.A.O. *see* Hawkes, N.D.
Thomas, H.J.W. *see* Dove-Edwin, I.
Thompson, M. *see* Bardhan, K.D.
thromboxane synthase inhibitor, 1323
thymosin, 1907
Tibble, J., Sigthorsson, G., Caldwell, C., Palmer, R.H. & Bjarnason, I. Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats, 2009
tissue concentration, 53
TNBS-induced rat colitis, 2035
TNF, 1827
To, K.F. *see* Chan, F.K.L.

© 2001 Blackwell Science Ltd

To, K.F. *see* Leung, W.K.
To, K.F. *see* Yu, J.
To, K.F., Chan, F.K.L., Cheng, A.S.L., Lee, T.L., Ng, Y.P. & Sung, J.J.Y. Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer, 25
Todd, J.A., Weston, T., Macdonald, T.M., Johnston, D.A. & Dillon, J.F. The prescribing of acid suppressants prior to the endoscopic diagnosis of Barrett's oesophagus and oesophagitis, 221
Todisco, A. *see* Manes, G.
Toledo, T.K. & Dipalma, J.A. Review article: colon cleansing preparation for gastrointestinal procedures, 605
Tong, T.S.M. *see* Wong, B.C.Y.
Tonini, M. *see* De Giorgio, R.
topical mesalazine, 251
Toti, G.L. *see* Testoni, P.A.
toxicity, 1301
Toyota, T. *see* Koike, T.
transforming growth factor α, 989
transforming growth factor-β1, 1667
transient lower oesophageal sphincter relaxation, 1357
transit, 653
transplant, 1843
travel, 1139
Travis, S. *see* Green, J.R.B.
treatment and antibiotics resistance, 843
treatment, 145, 1061, 1409, 1619, 1851
Triadafilopoulos, G. *see* Fitzgerald, R.C.
tricyclic anti-depressants, 1915
trimebutine, 1233
Tripathi, D. & Hayes, P.C. Review article: a drug therapy for the prevention of variceal haemorrhage, 291
triple antimicrobial therapy, 1037
triple regimens, 1009
triple therapy, 613, 1017, 1023, 1067, 1199, 1479, 1777
Trudgill, N.J., Hussain, F.N., Moustafa, M., Ajjan, R., D'Amato, M. & Riley, S.A. The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease, 1357
Tsang, S.W.C., Chan, H.L.Y., Leung, N.W.Y., Chau, T.N., Lai, S.T., Chan, F.K.L. & Sung, J.J.Y. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection, 1737
Tseng, H.-H. *see* Hsu, P.-I.
tubular proteinuria, 1131
tumour development, 1219
tumour necrosis factor-α, 865, 1515, 1975
Tunturi-Hihnala, H. *see* Talley, N.J.
Tutuian, R. *see* Xue, S.
Tytgat, G.N.J. *see* Hurenkamp, G.J.B.
Tytgat, G.N.J. *see* Vreeburg, E.M.
Tytgat, G.N.J. *see* Wingate, D.
Tzias, V. *see* Kamberoglou, D.

ulcer bleeding, 19
ulcer haemorrhage, 1947
ulcer healing, 1947, 2009
ulcer, 11
ulcerative colitis, 53, 363, 475, 653, 665, 731, 1101, 1131, 1307, 1549, 1699
ultrasonography, 181
uncoupler, 1837
upper gastrointestinal endoscopy, 217
uptake kinetics, 2027
Urae, A. *see* Horai, Y.
urea breath test, 1023
urea, 1763
Ureal, 1763
urine, 699
ursodeoxycholic acid, 123, 1427
Usai, P. *see* Vecchi, M.

vac*A, 1271*
Vaccaro, A. *see* Di Marco, V.
Vaezi, M.F. *see* Fackler, W.K.
Vainer, D. *see* Nielsen, O.H.
Vaira, D. *see* Manes, G.
Vakil, N.B., Shaker, R., Johnson, D.A., Kovacs, T., Baerg, R.D., Hwang, C., D'Amico, D. & Hamelin, B. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety, 927
Valatas, V. *see* Matrella, E.
Valerio, G. *see* Pilotto, A.
validation, 1155
validity, 207
Van Asbeck, B.S. *see* Oldenburg, B.
Van Assche, G. *see* Cornillie, F.
Van Berge Henegouwen, G.P. *see* Oldenburg, B.
Van Berge Henegouwen, G.P. *see* Schwartz, M.P.
Van Den Bogaerde, J., Kamm, M.A. & Knight, S.C. Immune sensitization to food, yeast and bacteria in Crohn's disease, 1647
Van Der Ende, A. *see* Hurenkamp, G.J.B.
Van Der Hulst, R.W.M. *see* Hurenkamp, G.J.B.
Van Der Voort, I.R. *see* Pohle, T.
Van Der Zon, A.M. *see* Verspaget, H.W.
Van Dooren, I.M.A. *see* Schoon, E.J.
Van Erpecum, K.J. *see* Moschetta, A.
Van Hogezand, R.A. *see* Verspaget, H.W.
Van Oijen, A.H.A.M. *see* Janssen, M.J.R.
Van Rensburg, C. *see* Bardhan, K.D.
Van Zanten, S.V. *see* Talley, N.J.
Vanberge-Henegouwen, G.P. *see* Moschetta, A.
variceal bleeding, 575, 1109
varices, 291
Vasina, V. *see* De Giorgio, R.
Vecchi, M., Meucci, G., Gionchetti, P., Beltrami, M., Di Maurizio, P., Beretta, L., Ganio, E., Usai, P., Campieri, M., Fornaciari, G. & De Franchis, R. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study, 251
Vela, M.F. *see* Srinivasan, R.
Veldhuyzen Van Zanten, S.J.O. *see* Redstone, H.A.

© 2001 Blackwell Science Ltd

Venzon, D.J. *see* Corleto, V.D.
Verbeek, A.L.M. *see* Janssen, M.J.R.
Verbeek, A.L.M. *see* Laheij, R.J.F.
Verbeke, S. *see* Gotteland, M.
Verghi, F. *see* Carroccio, A.
Verheij, T.J.M. *see* Weijnen, C.F.
Verheugt, F.W.A. *see* Laheij, R.J.F.
Verlinden, M. *see* Talley, N.J.
Vermeer, C. *see* Schoon, E.J.
Verspaget, H.W., Van Der Zon, A.M., Gao, Q. & Van Hogezand, R.A. Letter to the Editors, 2049
Villa, E. *see* Battezzati, P.M.
Villani, M.R. *see* Perri, F.
virologic response, 551
vitamin A, 973
vitamin C, 677
Vogelsang, H. *see* Reinisch, W.
Vogelsang, H., Schwarzenhofer, M., Steiner, B., Wyatt, J. & Oberhuber, G. *In vivo* and *in vitro* permeability in coeliac disease, 1417
Von Der Weid, P.-Y. Review article: lymphatic vessel pumping and inflammation—the role of spontaneous constrictions and underlying electrical pacemaker potentials, 1115
Vreeburg, E.M., Levi, M., Rauws, E.A.J., Deventer, S.J.H.V., Snel, P., Bartelsman, J.W.F.M., Ten Cate, J.W. & Tytgat, G.N.J. Enhanced mucosal fibrinolytic activity in gastroduodenal ulcer haemorrhage and the beneficial effect of acid suppression, 639

Wagner, C. *see* Cornillie, F.
Wainwright, M. *see* Selvasekar, C.R.
Waizenhoefer, A. *see* Pehl, C.
Waldhör, T. *see* Reinisch, W.
Waldum, H.L. Letter to the Editors, 727
Waldum, H.L. *see* Humphries, T.J.
Walker, S.J. *see* Selvasekar, C.R.
walking, 151
Wang, J.-L. *see* Chinese National Cooperative Study Group For Helicobacter Pylori
Wang, W.H. *see* Wong, B.C.Y.
Wardi, Y. *see* Shirin, H.
Wass, J.A.H. *see* Pereira, S.P.
Watanabe, M. *see* Adachi, K.
Watkins, H.C. *see* Green, J.R.B.
Watson, S.A. *see* Smith, A.M.
wedged hepatic venous pressure, 857
Weijnen, C.F., De Wit, N.J., Numans, M.E., Kuipers, E.J., Hoes, A.W. & Verheij, T.J.M. *Helicobacter pylori* testing in the primary care setting: which diagnostic test should be used?, 1205
Wendl, B. *see* Pehl, C.
Weston, T. *see* Todd, J.A.
Wettstein, A. *see* Meier, R.
whole blood test, 1205
Wigglesworth, J. *see* Jacob, M.
Wiklund, I.K. *see* Longstreth, G.F.
Wilcox, C.M. *see* Arguedas, M.R.
Williams, A. *see* Arnott, I.D.R.
Williams, D., O'Kelly, P., Kelly, A. & Feely, J. Lack of symptom benefit following presumptive *Helicobacter pylori* eradication therapy in primary care, 1769
Williams, G. *see* Green, J.
Williams, J. *see* Hawkes, N.D.
Williams, J.G. *see* Ragunath, K.
Willich, S.N. *see* Leodolter, A.
Wilson, C.G. *see* Perkins, A.C.
Wilson, I.K. *see* Longstreth, G.F.
Wingate, D., Phillips, S.F., Lewis, S.J., Malagelada, J.-R., Speelman, P., Steffen, R. & Tytgat, G.N.J. Guidelines for adults on self-medication for the treatment of acute diarrhoea, 773
Winstanley, T. *see* Parsons, H.K.
Wong, B.C.Y. *see* Szeto, M.L.
Wong, B.C.Y. *see* Wong, W.M.
Wong, B.C.Y. *see* Xia, H.H.-X.
Wong, B.C.Y., Wang, W.H., Berg, D.E., Fung, F.M.Y., Wong, K.W., Wong, W.M., Lai, K.C., Cho, C.H., Hui, W.M. & Lam, S.K. High prevalence of mixed infections by *Helicobacter pylori* in Hong Kong: metronidazole sensitivity and overall genotype, 493
Wong, B.C.Y., Wang, W.H., Wong, W.M., Lau, G.K.K., Fung, F.M.Y., Kung, N.N.S., Chu, K.M., Lai, K.C., Hu, W.H.C., Hu, F.L., Liu, X.G., Chan, C.K., Yuen, M.F., Hui, W.M. & Lam, S.K. Three-day lansoprazole quadruple therapy for *Helicobacter pylori*-positive duodenal ulcers: a randomized controlled study, 843
Wong, B.C.Y., Wong, W.M., Wang, W.H., Fung, F.M.Y., Lai, K.C., Chu, K.M., Yuen, S.T., Leung, S.Y., Hu, W.H.C., Yuen, M.F., Lau, G.K.K., Chan, C.K. & Lam, S.K. One-week ranitidine bismuth citrate-based triple therapy for the eradication of *Helicobacter pylori* in Hong Kong with high prevalence of metronidazole resistance, 403
Wong, B.C.Y., Wong, W.M., Wang, W.H., Tang, V.S.Y., Young, J., Lai, K.C., Yuen, S.T., Leung, S.Y., Hu, W.H.C., Chan, C.K., Hui, W.M. & Lam, S.K. An evaluation of invasive and non-invasive tests for the diagnosis of *Helicobacter pylori* infection in Chinese, 505
Wong, B.C.Y., Wong, W.M., Yee, Y.K., Hung, W.K., Yip, A.W.C., Szeto, M.L., Li, K.F., Lau, P., Fung, F.M.Y., Tong, T.S.M., Lai, K.C., Hu, W.H.C., Yuen, M.F., Hui, C.K. & Lam, S.K. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of *Helicobacter pylori* infection, 1967
Wong, K.W. *see* Wong, B.C.Y.
Wong, K.W. *see* Wong, W.M.
Wong, K.W. *see* Xia, H.H.-X.
Wong, S.K.H. *see* Wu, J.C.Y.
Wong, S.Y. *see* Xia, H.H.-X.
Wong, W. *see* Chun Yu, B.
Wong, W.M. *see* Wong, B.C.Y.
Wong, W.M. *see* Xia, H.H.-X.
Wong, W.M., Wong, B.C.Y., Li, T.M., Wong, K.W., Cheung, K.L., Fung, F.M.Y., Xia, H.H.X. & Lam, S.K. Twenty-minute 50 mg ^{13}C-urea breath test without test meal for the diagnosis of *Helicobacter pylori* infection in Chinese, 1499
Wright, J.P. *see* Carty, E.

© 2001 Blackwell Science Ltd

Wright, N.A. *see* Sasaki, M.
Wu, J.C.Y. *see* Chan, F.K.L.
Wu, J.C.Y., Lai, A.C.W., Wong, S.K.H., Chan, F.K.L., Leung, W.-K. & Sung, J.J.Y. Dysfunction of oesophageal motility in *Helicobacter pylori*-infected patients with reflux oseophagitis, 1921
Wyatt, J. *see* Vogelsang, H.

Xia, H.H.X. *see* Wong, W.M.
Xia, H.H.-X., Wong, B.C.Y., Wong, K.W., Wong, S.Y., Wong, W.M., Lai, K.C., Hu, W.H.C., Chan, C.K. & Lam, S.K. Clinical and endoscopic characteristics of non-*Helicobacter pylori*, non-NSAID duodenal ulcers: a long-term prospective study, 1875
Xiao, F. *see* Shirai, N.
Xiao, F., Furuta, T., Takashima, M., Shirai, N. & Hanai, H. Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by *Helicobacter pylori* infection in C57BL/6 mice, 875
Xiao, S.-D. *see* Chinese National Cooperative Study Group For Helicobacter Pylori
Xiao, S.-D. *see* Lu, H.
Xidakis, C. *see* Matrella, E.
Xue, S. *see* Katz, P.O.
Xue, S., Katz, P.O., Banerjee, P., Tutuian, R. & Castell, D.O. Bedtime H_2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors, 1351

Yaghoobi, M. *see* Mikaeli, J.
Yamada, T. *see* Nagahara, A.
Yamaoka, Y. *see* Shiotani, A.
Yao, T. *see* Horai, Y.
Yee, G.C. *see* You, J.H.S.
Yee, Y.K. *see* Szeto, M.L.
Yee, Y.K. *see* Wong, B.C.Y.
Yip, W.C. *see* Wong, B.C.Y.
yoghurt, 543
Yomota, E. *see* Nogi, K.
Yoneda, M. *see* Hasegawa, T.
Yoneta, T. *see* Suzuki, H.
Yoshida, N. *see* Naito, Y.
Yoshikawa, T. *see* Naito, Y.
You, J.H.S., Lee, K.K.C., Ho, S.S.S., Sung, J.J.Y., Kung, N.N.S., Yung, M., Lee, C. & Yee, G.C. Economic analysis of four triple regimens for the treatment of *Helicobacter pylori*-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong, 1009
Young, J. *see* Wong, B.C.Y.
Yu, J. *see* Leung, W.K.
Yu, J., Leung, W.K., Ng, E.K.W., To, K.F., Ebert, M.P.A., Go, M.Y.Y., Chan, W.Y., Chan, F.K.L., Chung, S.C.S., Malfertheiner, P. & Sung, J.J.Y. Effect of *Helicobacter pylori* eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia, 1505
Yuen, M.-F. *see* Hui, C.-K.
Yuen, M.F. *see* Wong, B.C.Y.
Yuen, S.T. *see* Wong, B.C.Y.
Yung, M. *see* You, J.H.S.

Zagari, R.M. *see* Bazzoli, F.
Zaïm, M. *see* Bruley Des Varannes, S.
Zambelli, A. *see* Testoni, P.A.
Zambia, 973
Zar, S., Kumar, D. & Benson, M.J. Review article: food hypersensitivity and irritable bowel syndrome, 439
Zarzuelo, A. *see* Gálvez, J.
Zavallone, A. *see* Oderda, G.
Zelmac, 277
Zerbib, F. *see* Galmiche, J.P.
Zhang, D.-Z. *see* Lu, H.
Zhang, Y. *see* Reinisch, W.
Zhou, L.-Y. *see* Chinese National Cooperative Study Group For Helicobacter Pylori
zinc sulfate, 715
Zollinger–Ellison syndrome, 87, 669, 1555, 1795
Zubaidi, S. *see* Robinson, M.
Zuin, G. *see* Carroccio, A.
Zuin, M. *see* Battezzati, P.M.
Zuin, M. *see* The British-Italian Gallstone Study Group
Zullo, A., Hassan, C., Campo, S.M.A., Lorenzetti, R., Febbraro, I., De Matthaeis, M., Porto, D. & Morini, S. A triple therapy regimen after failed *Helicobacter pylori* treatments, 1193
Zulu, I. *see* Kelly, P.

© 2001 Blackwell Science Ltd